神経疾患治療ストラテジー

出版社： 中山書店
著者：
発行日： 2017-09-15
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784521745435
電子書籍版： 2017-09-15 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

15,400 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

15,400 円(税込)

購入する

商品紹介

神経疾患の各種治療法は何をターゲットとして何を解決しようとしているのかという視点から，〈アクチュアル脳・神経疾患の臨床〉シリーズ既刊全11巻でとりあげた疾患を横断的に解説．既に導入されている治療や根本治療の可能性について，各分野の専門家が最新知見を紹介している．近年劇的に進歩した「神経疾患治療」のすべてがわかる神経内科医の必携書．

目次

  • 神経疾患治療ストラテジー

    ―目次―

    1．神経疾患の治療法
    2．今後の治療法への展開
    3．ここが知りたい―今後の治療開発に向けて

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 神経疾患の治療法

P.12 掲載の参考文献
1) Peaston MJ, Bianchine JR. Metabolic studies and clinical observations during L-dopa treatment of Parkinson's disease. Br Med J 1970 ; 1 : 400-403.
 
2) Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984 ; 7 : 35-49.
PubMed
3) Fahn S, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004 ; 351 : 2498-2508.
PubMed
4) Rajput AH, et al. Normal substantia nigra patients treated with levodopa : Clinical, therapeutic and pathological observations. Parkinsonism Relat Disord 2015 ; 21 : 1232-1237.
PubMed
5) Olanow CW, et al. Continuous dopamine-receptor treatment of Parkinson's disease : Scientific rationale and clinical implications. Lancet Neurol 2006 ; 5 : 677-687.
PubMed
6) Stocchi F, et al. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease : A clinical and pharmacokinetic study, Arch Neurol 2005 ; 62 : 905-910.
PubMed
7) Devos D ; French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009 ; 24 : 993-1000.
 
8) Poewe W, et al. Levodopa in the treatment of Parkinson's disease : An old drug still going strong. Clin Interv Aging 2010 ; 5 : 229-238.
PubMed
9) Lee WY, et al. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord 2008 ; 23 : 1696-1700.
PubMed
10) Fasano A, et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013 ; 28 : 1241-1249.
PubMed
11) Murata M, et al. Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson's disease patients. npj Parkinson's Disease 2016 ; 2 : 16020.
PubMed
デュオドーパ(R) 情報 (医療関係者向け) アッヴィ合同会社 https://abbvie-channel.com J contents/pages/duodopa.aspx
 
P.19 掲載の参考文献
1) 日本神経学会 (監修), 「認知症疾患治療ガイドライン」作成合同委員会 (編). 認知症疾患治療ガイドライン 2010. 東京 : 医学書院 ; 2010.
 
2) Scheltens P, et al. Alzheimer's disease. Lancet 2016 ; 388 (10043) : 505-517.
PubMed
3) Nees F. The nicotinic cholinergic system function in the human brain. Neuropharmacology 2015 ; 96 : 289-301.
PubMed
4) Tan CC, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease : A systematic review and meta-analysis. J Alzheimers Dis 2014 ; 41 : 615-631.
PubMed
5) Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006 Jan 25 ; (1) : CD005593.
 
6) 下濱俊. 高齢者の神経伝達機能を考慮したアセチルコリン系薬物による治療. 老年精神医学雑誌 2012 ; 23 : 952-958.
Medical*Online
7) Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement 2011 : 7 ; 270-279.
PubMed
8) Salloway S, et al. Efficacy of donepezil in mild cognitive impairment : A randomized placebo-controlled trial. Neurology 2004 ; 63 : 651-657.
PubMed
9) Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment : A clinical review. JAMA 2014 ; 312 (23) : 2551-2561.
PubMed
10) Parsons CG, et al. Memantine : A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology 2007 ; 53 : 699-723.
PubMed
11) Matsunaga S, et al. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease : A systematic review and meta-analysis. Int J Neuropsychopharmacol 2014 ; 18 (5). pii : pyu115. doi : 10.1093/ijnp/pyu115.
 
12) Robertson IH. A noradrenergic theory of cognitive reserve : Implications for Alzheimer's disease. Neurobiol Aging 2013 ; 34 : 298-308.
PubMed
13) Walker Z, et al. Lewy body dementias. Lancet 2015 ; 386 : 1683-1697.
 
14) Swainson R, et al. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions : Possible adverse effects of dopaminergic medication. Neuropsychologia 2000 ; 38 : 596-612.
 
15) Kwak Y, et al. Effect of dopaminergic medications on the time course of explicit motor sequence learnin g in Parkinson's disease. J Neurophysiol 2010 ; 103 : 942-949.
 
16) Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011 ; 134 : 2456-2477.
PubMed
17) Bang J, et al. Frontotemporal dementia. Lancet 2015 ; 386 : 1672-1682.
PubMed
18) Huey ED, et al. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006 ; 66 : 17-22.
PubMed
19) Hughes LE, et al. Improving response inhibition systems in frontotemporal dementia with citalopram. Brain 2015 ; 138 (Pt 7) : 1961-1975.
 
20) 池田学 (編). 日常診療に必要な認知症症候学. 東京 : 新興医学出版社 ; 2014.
 
21) Mendez MF, et al. Preliminary findings : Behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 2007 ; 15 (1) : 84-87.
PubMed
22) Boxer AL, et al. Memantine in patients with frontotemporal lobar degeneration : A multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013 ; 12 (2) : 149-156.
PubMed
23) Finger EC, et al. Oxytocin for frontotemporal dementia : A randomized dose-finding study of safety and tolerability. Neurology 2015 ; 84 : 174-181.
PubMed
P.26 掲載の参考文献
1) 松井真. MSの病態理解に必要な免疫学. 臨床神経学 2013 ; 53 : 898-901.
 
2) Ren T, Cidlowski JA. Antiinflammatory action of glucocorticoids--New mechanisms for old drugs. N Engl J Med 2005 ; 353 : 1711-1723.
 
3) Gold R, et al. Mechanism of action of glucocorticosteroid hormones : Possible implications for therapy of neuroimmunological disorders J Neuroimmunol 2001 ; 117 : 1-8.
PubMed
4) 柳瀬敏彦, 名和田新. 合成グルココルチコイド. 日本臨牀 1994 ; 52 : 578-582.
Medical*Online
5) 山本一彦 (編). 改訂版ステロイドの選び方・使い方ハンドブック. 東京 : 羊土社 ; 2011.
 
6) Yamazaki R, et al. Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Mult Scler 2016 : 22 : 1337-1348.
 
7) Watanabe S, et al. Low dose corticosteroids reduce relapse in neuromyelitis optica. Mult Scler 2007 ; 13 : 968-974.
PubMed
8) 日本神経学会 (監修), 「重症筋無力症診療ガイドライン」作成委員会 (編). 重症筋無力症診療ガイドライン 2014. 東京 : 南江堂 ; 2014.
 
9) 日本神経学会 (監修), 「慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン」作成委員会 (編). 慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン 2013. 東京 : 南江堂 ; 2013.
 
10) 三森経世 (編). 免疫抑制薬の選び方と使い方. 東京 : 南江堂 ; 2000.
 
11) 日本神経学会 (監修), 「多発性硬化症・視神経脊髄炎診療ガイドライン」作成委員会 (編). 多発性硬化症・視神経脊髄炎診療ガイドライン 2017. 東京 : 医学書院 ; 2017.
 
12) Farina C, et al. Glatiramer acetate in multiple sclerosis : Update on potential mechanisms of action. Lancet Neurol 2005 : 4 ; 567-575.
PubMed
13) Matsui M, et al. Japanese guidelines for fingolimod in multiple sclerosis : Putting into practice. Clin Exp Neuroimmunol 2014 ; 5 : 34-48.
 
14) Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007 ; 356 : 2622-2629.
PubMed
15) Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012 ; 367 : 2015-2025.
PubMed
P.36 掲載の参考文献
1) HERS HG. alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease) Biochem J 1963 ; 86 : 11-16,
PubMed
2) ポンペ病 (糖原病II型) ガイドライン編集委員会 (編). ポンペ病 (糖原病II型) 診断・治療ガイドライン改訂版. 東京 : イーエヌメディックス ; 2013.
 
3) Kishnani PS, et al. Recombinant human acid alpha-glucosidase : Major clinical benefits in infantile-onset Pompe disease. Neurology 2007 ; 68 : 99-109.
PubMed
4) Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease : A systematic literature review. J Neurol 2013 ; 260 : 951-959.
PubMed
5) Kishnarli PS, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 2010 ; 99 : 26-33.
 
6) Fukuda T, et al. Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann Neurol 2006 ; 59 : 700-708.
 
7) Raben N, et al. Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease : Implications for therapy. Mol Genet Metab 2010 ; 101 : 324-331.
PubMed
8) ファブリー病診断治療ハンドブック編集委員会 (編). ファブリー病診断治療ハンドブック 2015. 東京 : イーエヌメディックス ; 2015.
 
9) Beck M, et al. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease : A Fabry Outcome Survey analysis. Mol Genet Metab Rep 2015 ; 3 : 21-27.
PubMed
10) Germain DP, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 2015 ; 52 : 353-358.
PubMed
11) ゴーシェ病診断・治療ハンドブック編集委員会 (編). ゴーシェ病診断・治療ハンドブック 第2版. 東京 : イーエヌメディックス ; 2016.
 
12) Charrow J, et al. The Gaucher registry : Demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000 ; 160 : 2835-2843.
PubMed
13) Ida H, et al. Type 1 Gaucher disease : Phenotypic expression and natural history in Japanese patients. Blood Cells Mol Dis 1998 ; 24 : 73-81.
PubMed
14) 成田綾ほか. Gaucher病3型患者に対するケミカルシャペロン療法の効果. 脳と発達 2011 ; 43 : S248.
Medical*Online
15) Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009 ; 361 : 1651-1661.
PubMed
16) Nalls MA, et al. A multicenter study of glucocerebrosidase mutations in dementia with lewy bodies. JAMA Neurol 2013 ; 70 : 727-735.
PubMed
17) Cullen V, et al. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol 2011 ; 69 : 940-953.
 
P.46 掲載の参考文献
1) Aktas O, et al. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 2010 ; 6 : 373-382.
PubMed
2) Kappos L, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010 ; 362 : 387-401.
 
3) Goodin DS, et al. Assessment : The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review) : Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008 ; 71 : 766-773.
 
4) Kappos L, et al. Natalizumab treatment for multiple sclerosis : Updated recommendations for patient selection and monitoring. Lancet Neurol 2011 ; 10 : 745-758.
PubMed
5) Havrdova E, et al. Alemtuzumab in the treatment of multiple sclerosis : Key clinical trial results and considerations for use. Ther Adv Neurol Disord 2015 ; 8 : 31-45.
PubMed
6) Li R, et al. Cytokine-defined B cell responses as therapeutic targets in multiple sclerosis. Front Immunol 2016 ; 6 : 626-635.
PubMed
7) Pfender N, Martin R. Daclizumab (anti-CD25) in multiple sclerosis. Exp Neurol 2014 ; 262 : 44-51.
PubMed
8) Mi S, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 2007 : 13 : 1228-1233.
PubMed
9) Lennon VA, et al. A serum autoantibody marker of neuromyelitis optica : Distinction from multiple sclerosis. Lancet 2004 ; 364 : 2106-2112.
PubMed
10) Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica : Diagnostic and pathogenetic relevance. Nat Rev Neurol 2010 ; 6 : 383-392.
PubMed
11) Chihara N, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 2011 ; 108 : 3701-3706.
PubMed
12) Araki M, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica : A pilot study. Neurology 2014 ; 82 : 1302-1306.
PubMed
13) Pittock SJ, et al. Eculizumab in AQp4-IgG-positive relapsing neuromyelitis optica spectrum disorders : An open-label pilot study. Lancet Neurol 2013 ; 12 : 554-562.
PubMed
14) Jacob A, et al. Treatment of neuromyelitis optica with rituximab : Retrospective analysis of 25 patients. Arch Neurol 2008 ; 65 : 1443-1448.
PubMed
15) Kim SH, et al. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica : Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab. JAMA Neurol 2015 ; 72 : 989-995.
PubMed
16) Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012 ; 11 : 535-544.
PubMed
17) Fitzpatrick AM, et al. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher. Nerv Syst 2011 : 16 : 84-91.
PubMed
18) Dalakas MC, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009 ; 65 : 286-293.
PubMed
Klotz L, Wiendl H. Monoclonal antibodies in neuroinflammatory diseases. Expert Opin Biol Ther 2013 ; 13 : 831-846.
PubMed
Rommer PS, et al. Monoclonal antibodies in the treatment of neuroimmunological diseases. Curr Pharm Des 2012 ; 18 : 4498-4507.
PubMed
The International Multiple Sclerosis Genetics Consortium (IMSGC) ; Wellcome Trust Case Control Consortium 2 (WTCCC2), Sawcer A, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011 ; 476 : 214-219.
 
Wattjes MP, Barkhof F. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol 2014 ; 27 : 260-270.
PubMed
Sorensen P, et al. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol 2014 ; 261 : 1170-1177.
 
Faissner S, et al. Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Ther Adv Neurol Disord 2015 ; 8 : 233-238.
PubMed
P.55 掲載の参考文献
1) 大野行弘. てんかんの薬. 成田年 (監修), 疾患薬理学. 神奈川 : ネオメディカル ; 2016, pp. 193-202.
 
2) 日本神経学会 (監修), 「てんかん治療ガイドライン」作成委員会 (編). てんかん治療ガイドライン 2010. 東京 : 医学書院 ; 2010.
 
3) Marson AG, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy : An unblinded randomised controlled trial. Lancet 2007 ; 369 : 1000-1015.
 
4) Marson AG, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy : An unblinded randomised controlled trial. Lancet 2007 ; 369 : 1016-1026.
 
5) 佐藤岳史ほか. その他の症候と治療 : てんかん. 橋本信夫 (編), 脳神経外科臨床指針. 東京 : 中外医学社 ; 2002, pp20-33.
 
6) Jingami N, et al. A novel SCN1A mutation in a cytoplasmic loop in intractable juvenile myoclonic epilepsy without febrile seizures. Epileptic Disord 2014 ; 16 : 227-231.
 
7) Andersohn F, et al. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 2010 ; 75 : 335-340.
PubMed
8) Hitiris N, Brodie MJ. Modern antiepileptic drugs : Guidelines and beyond. Curr Opin Neurol 2006 ; 19 : 175-180.
 
9) Anderson GD, et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996 ; 60 : 145-156.
PubMed
10) Tokudome K, et al. Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic. Sci Rep 2016 ; 6 : 27420.
PubMed
11) 笹征史. レベチラセタムClinical Neuroscience 2011 ; 29 : 104-106.
 
12) Rogawski MA, et al. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res 2015 ; 110 : 189-205.
PubMed
13) Sada N, et al. Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science 2015 ; 347 : 1362-1367.
PubMed
14) Higurashi N, et al. A human Dravet syndrome model from patient induced pluripotent stem cells. Mol Brain 2013 ; 6 : 19.
 
P.62 掲載の参考文献
1) 平山惠造 (監修). 臨床神経内科学. 改訂6版. 13 神経筋接合部疾患. 東京 : 南山堂 ; 2015, pp. 538-555.
 
2) Iorio R, et al. Efficacy and safety of rituximab for myasthenia gravis : A systematic review and meta-analysis J Neurol 2015 ; 262 : 1115-1119.
PubMed
3) Howard JF Jr, et al ; MG Study Group. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 2013 ; 48 : 76-84.
 
4) Oh SJ, et al ; LEMS Study Group. Amifampridine phosphate (Firdapse(R)) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve 2016 ; 53 : 717-725.
 
5) Tarr TB, et al. Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. J Neurosci 2013 ; 33 : 10559-10567.
PubMed
6) 大野欽司. 先天性筋無力症候群. Clinical Neuroscience 2014 ; 32 (9) : 1006-1010.
 
7) Okada K, et al. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 2006 ; 312 (5781) : 1802-1805.
PubMed
8) Beeson D, et al. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 2006 ; 313 (5795) : 1975-1978.
PubMed
9) Liewluck T, et al. Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle Nerve 2011 ; 44 (5) : 789-794.
PubMed
10) Loochtan AI, et al. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 2015 ; 52 : 307-308.
PubMed
11) Jurkat-Rott K, et al. A calcium channel mutation causing hypokalemic periodic paralysis. Hum Mol Genet 1994 ; 3 : 1415-1419.
PubMed
12) Miller TM, et al. Correlating phenotype and genotype in the periodic paralyses. Neurology 2004 ; 63 : 1647-1655.
PubMed
13) Wu F, et al. Bumetanide prevents transient decreases in muscle force in murine hypokalemic periodic paralysis. Neurology 2013 ; 80 : 1110-1116.
PubMed
14) Sansone VA, et al. Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis. Neurology 2016 ; 86 (15) : 1408-1416.
PubMed
15) Cannon SC, et al. A sodium channel defect in hyperkalemic periodic paralysis : Potassium-induced failure of inactivation. Neuron 1991 ; 6 : 619-626.
PubMed
16) Cannon SC, et al. Theoretical reconstruction of myotonia and paralysis caused by incomplete inactivation of sodium channels. Biophys J 1993 ; 65 ; 270-288.
PubMed
17) Sansone V, Tawil R. Management and treatment of Andersen-Tawil syndrome (ATS). Neurotherapeutics 2007 ; 4 : 233-237.
PubMed
18) Plaster NM, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001 ; 105 : 511-519.
 
19) Kokunai Y, et al. A Kir3.4 mutation causes Andersen-Tawil syndrome by an inhibitory effect on Kir2.1. Neurology 2014 ; 82 : 1058-1064.
PubMed
20) 難病情報センター http://www.nanbyou.or.jp
 
21) Koch MC, et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science 1992 ; 257 : 797-800.
PubMed
22) Fialho D, et al. Chloride channel myotonia : Exon 8 hot-spot for dominant-negative interactions. Brain 2007 ; 130 (Pt 12) : 3265-3274.
 
23) Cannon SC. Voltage-sensor mutations in channelopathies of skeletal muscle J Physiol 2010 ; 588 : 1887-1895.
PubMed
24) Fukudome T, et al. Paramyotonia congenita due to a de novo mutation : A case report. Muscle Nerve 2003 ; 28 : 232-235.
 
25) Statland JM, et al. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia : A randomized controlled trial. JAMA 2012 ; 308 (13) : 1357-1365.
PubMed
26) 日本麻酔科学会安全委員会悪性高熱症WG. 悪性高熱症患者の管理に関するガイドライン 2016-安全な麻酔管理のために, 2016年8月. http://www.anesth.or.jp/guide/pdf/guideline_akuseikounetsu.pdf
 
27) Gillard EF, et al. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 1991 ; 11 (3) : 751-755.
PubMed
28) Harrison GG. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 1975 ; 47 (1) : 62-65.
PubMed
29) Spillane J, et al. Genetic neurological channelopathies : Molecular genetics and clinical phenotypes. J Neurol Neurosurg Psychiatry 2016 ; 87 : 37-48.
PubMed
30) Zhuchenko O, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet 1997 ; 15 : 62-69.
PubMed
31) Ophoff RA, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996 ; 87 : 543-552.
PubMed
32) Lennon VA, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005 ; 202 : 473-477.
 
33) Fukuda T, et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003 ; 53 : 21-28.
PubMed
P.73 掲載の参考文献
1) Lees KR, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006 ; 354 : 588-600.
PubMed
2) Bath PM, et al. Tirilazad for acute ischaemic stroke. Cochrane Database Svst Rev 2001 ; 4 : CD002087.
 
3) 後藤文男ほか. 脳血管障害急性期に対するAVS (Nicaraven) の有用性-多施設二重盲検法による検討. 臨牀と研究 1989 ; 66 : 3577-3596.
Medical*Online
4) 坂井文彦ほか. 急性期脳出血・脳梗塞患者に対するnicaravenの至適用量の検討-後期第II相二重盲検試験. 医学のあゆみ 1995 ; 175 : 767-798.
 
5) Yamaguchi T, et al. Ebselen in acute ischemic stroke : A placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke 1998 ; 29 : 12-17.
 
6) Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003 ; 15 : 222-229.
 
7) Yamashita T, et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab 2009 ; 29 : 715-725.
 
8) Kaste M, et al. Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke : New formulation and dosing regimen. Cerebrovasc Dis 2013 ; 36 : 196-204.
PubMed
9) Kim GH, et al. The Role of Oxidative Stress in Neurodegenerative Diseases. Exp Neurobiol 2015 ; 24 : 325-340.
PubMed
10) Yamazaki H, et al. Role of the Keap1/Nrf2 pathway in neurodegenerative diseases. Pathol Int 2015 ; 65 : 210-219.
PubMed
11) Warita H, et al. Oxidative damage to mitochondrial DNA in spinal motoneurons of transgenic ALS mice. Brain Res Mol Brain Res 2001 ; 89 : 147-152.
PubMed
12) Mimoto T, et al. Impaired antioxydative Keap1/Nrf2 system and the downstream stress protein responses in the motor neuron of ALS model mice. Brain Res 2012 ; 1446 : 109-118.
PubMed
13) Abe K, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 2014 ; 15 : 610-617.
PubMed
14) Chiurchiu V, et al. Is Modulation of Oxidative Stress an Answer? The State of the Art of Redox Therapeutic Actions in Neurodegenerative Diseases. Oxid Med Cell Longev 2016 ; 2016 : 7909380.
PubMed
15) 高橋愼一ほか. フマル酸ジメチル (BG-12). Clinical Neuroscience 2014 ; 32 : 1287-1290.
 
P.83 掲載の参考文献
1) Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995 ; 333 : 1581-1587.
 
2) Hacke W, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) JAMA 1995 ; 274 : 1017-1025.
PubMed
3) 日本脳卒中学会脳卒中ガイドライン委員会 (編). 脳卒中治療ガイドライン 2015. 東京 : 協和企画 ; 2015.
 
4) 日本脳卒中学会,日本脳神経外科学会, 日本脳神経血管内治療学会. 経皮経管的脳血栓回収用機器 適正使用指針, 第2版. 2015年4月. http://www.jsnet.umin.jp/sozai/info-shonin/150402noukessenn_shishin.pdf
 
5) Wang Y, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013 ; 369 : 11-19.
 
6) Yasaka M, et al. Clinical features of recurrent embolization in acute cardioembolic stroke. Stroke 1993 ; 24 : 1681-1685.
PubMed
7) Kobayashi S, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost 1997 ; 23 : 531-534.
PubMed
8) Antithrombotic Trialists' (ATT) Collaboration, Baigent C, et al. Aspirin in the primary and secondary prevention of vascular disease : Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009 ; 373 : 1849-1860.
PubMed
9) CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996 ; 348 : 1329-1339.
 
10) Uchiyama S, et al. The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients : Combined results of two Phase III, multicenter, randomized clinical trials. J Neurol 2009 ; 256 : 888-897.
PubMed
11) Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 2007 ; 357 : 2001-2015.
PubMed
12) Saito S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome : The PRASFIT-ACS study. Circ J 2014 ; 78 : 1684-1692.
PubMed
13) Johnston SC, et al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med 2016 ; 375 : 35-43.
 
14) Kamal AK, et al. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev 2011 ; (1) : CD008076.
PubMed
15) Lee M, et al. Risk-benefit profile of long-term dual-versus single-antiplatelet therapy among patients with ischemic stroke : A systematic review and meta-analysis. Ann Intern Med 2013 ; 159 : 463-470.
PubMed
16) Gage BF, et al. Validation of clinical classification schemes for predicting stroke : Results from the National Registry of Atrial Fibrillation. JAMA 2001 ; 285 : 2864-2870.
 
17) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). 心房細動治療 (薬物) ガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf
 
18) Connolly SJ, et al. Dabigatrarl versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 ; 361 : 1139-1151.
PubMed
19) Hori M, et al ; J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study-. Circ J 2012 ; 76 : 2104-2111.
 
20) Patel MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 ; 365 : 883-891.
PubMed
21) Granger CB, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011 ; 365 : 981-992.
PubMed
22) Giugliano RP, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013 ; 369 : 2093-2104.
PubMed
23) Toyoda K, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease : A prospective, multicenter, observational study. Stroke 2008 ; 39 : 1740-1745.
PubMed
24) Poels MM, et al. Prevalence and risk factors of cerebral microbleeds : An update of the Rotterdam scan study. Stroke 2010 ; 41 (10 SuppD: S103-S106.
 
25) Charidimou A, et al. Cerebral microbleeds and recurrent stroke risk : Systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. Stroke 2013 ; 44 : 995-1001.
PubMed
P.92 掲載の参考文献
1) 中村佳司, 小崎俊司. ボツリヌス毒素の作用メカニズム, Modern Physician 2011 ; 31 : 793-797.
 
2) Jacky BP, et al. Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A). PLoS Pathog 2013 ; 9 (5) : e1003369.
PubMed
3) Pal PK, et al. Head tremor in cervical dystonia. Can J Neurol Sci 2000 ; 27 : 137-142.
PubMed
4) 日本脳卒中学会脳卒中ガイドライン委員会 (編). 脳卒中治療ガイドライン 2015, 東京 : 協和企画 ; 2015, pp. 295-298.
 
5) Naumann M, et al. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months : A prospective study. Arch Dermatol 2003 ; 139 : 731-736.
PubMed
6) Diener HC, et al. OnabotulinumtoxinA for treatment of chronic migraine : Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010 ; 30 (7) : 804-814.
PubMed
7) Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine : Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010 ; 30 (7) : 793-803.
PubMed
8) Dodick DW, et al. OnabotulinumtoxinA for treatment of chronic migraine : Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010 ; 50 (6) : 921-936.
PubMed
9) Robertson CE, Garza I. Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine. Neuropsychiatr Dis Treat 2012 ; 8 : 35-48.
PubMed
10) Morenilla-Palao C, et al. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004 ; 279 (24) : 25665-25672.
PubMed
11) Safarpour D, et al. Botulinum toxin A (Botox) for treatment of proximal myofascial pain in complex regional pain syndrome : Two cases. Pain Med 2010 ; 11 (9) : 1415-1418.
PubMed
12) Sahai A, et al. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 2010 ; 75 (3) : 552-558.
PubMed
13) Campbell JD, et al. Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics : A review of published evidence. BMC Urol 2009 ; 9 : 18.
PubMed
14) Ouslander JG. Management of overactive bladder. N Engl J Med 2004 ; 350 : 786-789.
PubMed
15) da Silva CM, Cruz F. Has botulinum toxin therapy come of age : What do we know, what do we need to know, and should we use it? Curr Opin Urol 2009 ; 19 (4) : 347-352.
 
16) Cordivari C, et al. New therapeutic indications for botulinum toxins, Mov Disord 2004 ; 19 (Suppl 8) : S157-S161.
 
17) Naumann M, et al. Assessment : Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review) : Report of the Therapeutic and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008 ; 70 : 1707-1714.
 
18) Jackson CE, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009 ; 39 : 137-143.
PubMed
19) Nobrega AC, et al. Does botulinum toxin injection in parotid glands interfere with swallowing dynamics of Parkinson's disease patients? Clin Neurol Neurosurg 2009 ; 111 : 430-432.
PubMed
20) Babinski J. Hemispasme facial peripherique. Nouvelle iconographie de la Salpetriere 1905 ; 18 : 418-423.
 
21) Stamey W, Jankovic J. The other Babinski sign in hemifacial spasm. Neurology 2007 ; 69 (4) : 402-404.
 
Perotto AO (著), 栢森良二 (訳). 筋電図のための解剖ガイド 四肢・体幹 第3版. 新潟 : 西村書店 ; 1997.
 
Wolfgang Jost, et al. Pictorial Atlas of Botulinum Toxin Injection : Dosage, Localization, Application. IL, USA : Quintessence Pub Co ; 2008/梶龍兒 (監訳). ボツリヌス療法アトラス. 東京 : 医学書院 ; 2012.
 
P.103 掲載の参考文献
1) 日本神経学会ほか (監修), 「細菌性髄膜炎診療ガイドライン」作成委員会 (編), 細菌性髄膜炎診療ガイドライン 2014. 東京 : 南江堂 ; 2014. ppxi-xii, 1-123.
 
2) Thwaites G, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 2009 ; 59 : 167-187.
 
3) Takahashi K, et al. Hospital-based study of the distribution of pathogens in adult bacterial meningitis with underlying disease in Tokyo, Japan. Neurol Clin Neurosci 2017 ; 5 : 8-17.
 
4) MacIntyre PB, et al. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA 1997 ; 278 : 925-931.
 
5) Mongelluzzo J, et al. Corticosteroids and mortality in children with bacterial meningitis. JAMA 2008 ; 299 : 2048-2055.
PubMed
6) de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002 ; 347 : 1549-1556.
PubMed
7) van de Beek D, et al. Adjunctive dexamethasone in bacterial meningitis : A meta-analysis of individual patient data. Lancet Neurol 2010 ; 9 : 254-263.
PubMed
8) Butcher NJ, et al. Pharmacogenetics of the arylamine N-acetyltransferases Pharmacogenomics J 2002 ; 2 : 30-42.
PubMed
9) Ohno M, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int Tuberc Lung Dis 2000 ; 4 : 256-261.
PubMed
10) Kubota R, et al. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2. Eur J Clin Pharmacol 2007 ; 63 : 927-933.
PubMed
11) Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008 ; (1) : CD002244.
PubMed
12) Thwaites GE, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004 ; 351 : 1741-1751.
PubMed
13) Perfect JR, et al. Clinical practice guidelines for the management of cryptococcal disease : 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010 ; 50 : 291-322.
 
14) Ecevit IZ, et al. The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients : A call for better disease recognition and evaluation of adjuncts to antifungal therapy. Clin Infect Dis 2006 ; 42 : 1443-1447.
 
15) Pappas PG, et al. Clinical practice guidelines for the management of candidiasis : 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009 ; 48 : 503-535.
 
16) Hamill RJ, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis : A randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis 2010 ; 51 : 225-232.
PubMed
17) Walsh TJ, et al. Treatment of aspergillosis : Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008 ; 46 : 327-360.
 
亀井聡. 細菌性髄膜炎の診断と治療-ガイドラインから. 神経治療 2016 ; 33 : 135-140.
Medical*Online
P.109 掲載の参考文献
1) Louis DN, et al. The 2016 World Health Organization Classification of Tulnors of the Central Nervous System : Asummary. Acta Neuropathol 2016 ; 131 (6) : 803-820.
 
2) Walker MD, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980 ; 303 (23) : 1323-1329.
PubMed
3) Takakura K, et al. Effects of ACNU and radiotherapy on malignant glioma, J Neurosurg 1986 ; 64 (1) : 53-57.
PubMed
4) Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 ; 352 (10) : 987-996.
PubMed
5) Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005 ; 52 (10) : 997-1003.
 
6) Ohka F, et al. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PloS One 2011 ; 6 (8) : e23332.
PubMed
7) Friedman HS, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clinical Oncol 2009 ; 27 (28) : 4733-4740.
PubMed
8) Nagane M, et al. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol 2012 ; 42 (10) : 887-895.
PubMed
9) Chinot OL, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014 ; 370 (8) : 709-722.
PubMed
10) Gilbert MR, et al. A randomized trial of bevacizumab for newly diagnosed glioblastorna. N Engl J Med 2014 ; 370 (8) : 699-708.
PubMed
11) Sandmann T, et al. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide : Retrospective Analysis of the AVAglio Trial. J Clin Oncol 2015 ; 33 (25) : 2735-2744.
 
12) Brem H, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995 ; 345 (8956) : 1008-1012.
PubMed
13) Westphal M, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003 : 5 (2) : 79- 88.
 
14) Jameson JL, Longo DL. Precision medicine--personalized, problematic, and promising. N Engl J Med 2015 ; 372 (23) : 2229-2234.
PubMed
15) Suzuki H, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 2015 ; 47 (5) : 458-468.
PubMed
16) Dang L, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009 ; 462 (7274) : 739-744.
PubMed
17) Figueroa ME, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010 ; 18 (6) : 553-567.
 
18) Rohle D, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013 ; 340 (6132) : 626-630.
PubMed
19) Schwartzentruber J, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012 ; 482 (7384) : 226-231.
PubMed
20) Hashizume R, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med 2014 ; 20 (12) : 1394-1396.
PubMed
21) Jones DT, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008 ; 68 (21) : 8673-8677.
PubMed
22) Jones DT, et al. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549 : BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009 ; 28 (20) : 2119-2123.
 
23) Brat DJ, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 2015 ; 372 (26) : 2481-2498.
PubMed
24) Verhaak RG, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010 ; 17 (1) : 98-110.
PubMed
P.119 掲載の参考文献
1) Low PA, Singer W. Management of neurogenic orthostatic hypotension : An update. Lancet Neurol 2008 ; 7 : 451-458.
PubMed
2) Naftd JP, Hardy SGP. 自律神経遠心系. Duane E. Haines (著), 高橋昭 (監), 岩瀬敏, 佐橋功 (編), ヘインズ神経科学-その臨床応用. 東京 : エルゼビア・ジャパン ; 2008, pp. 491-506.
 
3) Espay AJ, et al. Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies : Prioritisation of treatment targets. Lancet Neurol 2016 ; 15 : 954-966.
PubMed
4) Udow SJ, et al. 'Under pressure' : Is there a link between orthostatic hypotension and cognitive impairment in α-synucleinopathies? J Neurol Neurosurg Psychiatry 2016 ; 87 (12) : 1311-1321.
 
5) Iwase S, et al. Role of sympathetic nerve activity in the process of fainting. Front Physiol 2014 ; 5 : 343.
PubMed
6) Seppi K, et al. The Movement Disorder Society Evidence-Based Medicine Review Update : Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011 ; 26 Suppl 3 : S42-S80.
 
7) Singer W, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006 ; 63 ; 513-518.
PubMed
8) Gormley EA, et al ; American Urological Association ; Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults : AUA/SUFU guideline amendment. J Urol 2015 ; 193 : 1572-1580.
 
9) Sakakibara R, et al. Parkinson's Disease Subcomittee, The Neurourology Promotion Committee in The International Continence Society. A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourol Urodyn 2016 ; 35 : 551-563.
PubMed
10) Novara G, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008 ; 54 (4) : 740-763.
PubMed
11) Warren K, et al. Mirabegron in overactive bladder patients : Efficacy review and update on drug safety. Ther Adv Drug Saf 2016 ; 7 : 204-216.
PubMed
12) Fasano A, et al. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2015 ; 14 : 625-639.
PubMed
13) American Gastroenterological Association, Bharucha AE, et al. American Gastroenterological Association medical position statement on constipation. Gastroenterology 2013 ; 144 : 211-217.
PubMed
14) Rao SS, et al. Diagnosis and management of chronic constipation in adults. Nat Rev Gastroenterol Hepatol 2016 ; 13 : 295-305.
PubMed
15) Li F, et al. Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome : A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mayo Clin Proc 2016 ; 91 : 456-468.
PubMed
16) Risacher SL, et al. Alzheimer's Disease Neuroimaging Initiative. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol 2016 ; 73 : 721-732.
 
P.126 掲載の参考文献
1) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition. Arlington, VA : American Psychiatric Association ; 2013.
 
2) 日本うつ病学会 気分障害の治療ガイドライン作成委員会. 日本うつ病学会治療ガイドライン II. うつ病 (DSM-5) /大うつ病性障害 2016. http://www.secretariat. ne.jp/jsmd/mood_disorder/img/160731.pdf
 
3) 日本神経精神薬理学会 (編). 統合失調症薬物治療ガイドライン. 東京 : 医学書院 ; 2016.
 
4) 藤瀬昇, 池田学. うつ病と認知症との関連について. 精神神経学雑誌 2012 ; 114 : 276-282.
 
5) Drijgers RL, et al. Pharmacological treatment of apathy in neurodegenerative diseases : A systematic review. Dement Geriatr Cogn Disord 2009 ; 28 : 13-22.
PubMed
6) Jorge RE, et al. Mortality and poststroke depression : A placebo-controlled trial of antidepressants. Am J Psychiatry 2003 ; 160 : 1823-1829.
PubMed
7) 樋口輝彦 (監修). 認知症などの器質性疾患の前触れとしてのうつ病・うつ状態. 大阪 : 医薬ジャーナル社 ; 2016.
 
8) Gartlehner G, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder : An updated meta-analysis. Ann Intern Med 2011 ; 155 : 772-785.
PubMed
9) 厚生労働省医薬食品局. 医薬品・医療機器等安全性情報 No. 258, 2009. http://www1.mhlw.go.jp/kinkyu/iyaku_j/iyaku_j/anzenseijyouhou/258.pdf
 
10) Moulton CD, et al. Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease. Mov Disord 2014 ; 29 : 1556-1561.
PubMed
11) Wang J, et al. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease : A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2015 ; 86 : 101-109.
PubMed
12) Thompson S, et al. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease : A metaanalysis. Can J Psychiatry 2007 ; 52 : 248-255.
PubMed
13) Ettinger A, et al. Depression and comorbidity in community-based patients with epilepsy or asthma. Neurology 2004 ; 63 : 1008-1014.
 
14) 萩原徹也ほか. 精神障害と幻覚妄想. 堀口淳 (編), 脳とこころのプライマリケア 6, 幻覚と妄想. 東京 : シナジー ; 2011, pp. 79-85.
 
15) Leucht S, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : A multiple-treatments meta-analysis. Lancet 2013 ; 382 : 951-962.
PubMed
16) Wenzel-Seifert K, et al. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Aruebl Int 2011 ; 108 : 687-693.
PubMed
17) 平成24年度厚生労働科学研究費補助金 (厚生労働科学特別研究事業). 認知症, 特にBPSDへの適切な薬物使用に関するガイドライン作成に関する研究斑. かかりつけ医のためのBPSDに対応する向精神薬使用ガイドライン, 2013. http://www.mhlw.go.jp/stf/houdou/2r98520000036k0c-att/2r98520000036klt.pdf
 
18) Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease : A review. JAMA 2014 ; 311 : 1670-1683.
PubMed
19) West S, Kenedi C. Strategies to prevent the neuropsychiatric side-effects of corticosteroids : A case report and review of the literature. Curr Opin Organ Transplant 2014 ; 19 : 201-208.
 
20) Magro-Checa C, et al. Management of Neuropsychiatric Systemic Lupus Erythematosus : Current Approaches and Future Perspectives. Drugs 2016 ; 76 : 459-483.
PubMed
P.136 掲載の参考文献
1) American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults J Am Geriatr Soc 2015 ; 63 : 2227-2246.
 
2) O'Mahony D, et al. STOPP/START criteria for potentially inappropriate prescribing in older people : Version 2. Age Ageing 2015 ; 44 : 213-218.
PubMed
3) 日本老年医学会 (編). 高齢者の安全な薬物療法ガイドライン 2015. 東京 : メジカルビュー社 : 2015.
 
4) Kuzuya M, et al. Factors associated with nonadherence to medication in community-dwelling disabled older adults in Japan. J Am Geriatr Soc 2010 ; 58 : 1007-1009.
PubMed
5) 日本老年医学会. 「高齢者の終末期の医療およびケア」に関する日本老年医学会の「立場表明」2012. 日老医誌 2012 ; 49 : 381-386.
 
6) 後藤恵子. 服薬アドヒアランスとプラセボ効果に配慮した服薬指導. 薬局 2012 ; 63 (12) : 3528-3534.
 
7) Charlesworth CJ, et al. Polypharmacy among adults aged 65 years and older in the United States : 1988-2010. J Gerontol A Biol Sci Med Sci 2015 ; 70 : 989-995.
PubMed
8) 鳥羽研二. 非薬物療法. 臨牀と研究 2016 ; 93 : 459-462.
Medical*Online
9) 矢吹拓. ポリファーマシーに対する多職種チームの取り組み-入院患者を対象としたポリファーマシー外来. 第21回日本緩和医療学会学術大会 ; 2016, S227.
 
10) Day JC, et al. A self-rating scale for measuring neuroleptic side-effects : Validation in a group of schizophrenic patients. Br J Psychiatry 1995 ; 166 : 650-653.
 
11) Jung HY, et al. Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia. Hum Psychopharmacol 2005 ; 20 : 41-45.
PubMed
12) Rudolph JL, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008 ; 168 : 508-513.
PubMed
13) Matsuda Y, et al. Yokukansan in the treatment of behavioral and psychological symptoms of dementia : A systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol 2013 ; 28 : 80-86.
PubMed
14) Sepehry AA, et al. Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression : A meta-analysis of depression and cognitive outcomes. Drugs Aging 2012 ; 29 : 793-806.
PubMed
15) 日本脳卒中学会 脳卒中ガイドライン委員会 (編). 脳卒中治療ガイドライン 2015. 東京 : 協和企画 ; 2015.
 
P.148 掲載の参考文献
1) 日本静脈経腸栄養学会 (編). 静脈経腸栄養ガイドライン 第3版-静脈・経腸栄養を適正に実施するためのガイドライン. 東京 : 照林社 ; 2013.
 
2) Detsky AS, et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr 1987 ; 11 (1) : 8-13.
PubMed
3) Corrigan ML, et al. Nutrition in the stroke patient. Nutr Clin Pract 2011 ; 26 : 242-252.
PubMed
4) Gillette-Guyonnet S, et al. Weight loss in Alzheimer disease. Am J Clin Nutr 2000 ; 71 : 637S-642S.
PubMed
5) Sheard JM, et al. Prevalence of malnutrition in Parkinson's disease : A systematic review. Nutr Rev 2011 ; 69 : 520-532.
PubMed
6) Mann G, et al. Swallowing function after stroke : Prognosis and prognostic factors at 6 months. Stroke 1999 ; 30 (4) : 744-748.
PubMed
7) Hinchey JA, et al. Formal dysphagia screening protocols prevent pneumonia. Stroke 2005 ; 36 : 1972-1976.
PubMed
8) Dennis M, et al. FOOD : A multicentre randomised trial evaluating feeding policies in patients admitted to hospital with a recent stroke. Health Technol Assess 2006 : 10 : iii-iv, ix-x, 1-120.
 
9) Dennis MS, et al. Effect of timing and method of enteral tube feeding for dysphagic stroke patients (FOOD) : A multicentre randomised controlled trial. Lancet 2005 ; 365 (9461) : 764-772.
PubMed
10) National Institute for Health and Care Excellence, National Collaborating Centre for Chronic Conditions . Parkinson's Disease : National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. NICE 2006 Jun : CG35.
 
11) 若林秀隆, 栢下淳. 摂食嚥下障害スクリーニング質問紙票EAT-10の日本語版作成と信頼性・妥当性の検証. 静脈経腸栄養 2014 ; 29 (3) : 871-876.
 
12) Cushing ML, et al. Parkinson's disease : Implications for nutritional care. Can J Diet Pract Res 2002 ; 63 : 81-87.
PubMed
13) Cereda E, et al. Low-protein and protein-redistribution diets for Parkinson's disease patients with motor fluctuations : A systematic review. Mov Disord 2010 ; 25 (13) : 2021-2034.
PubMed
14) Chio A, et al. Prognostic factors in ALS : A critical review. Amyotroph Lateral Scler 2009 ; 10 (5-6) : 310-323.
 
15) Miller RG, et al. Practice parameter update : Tthe care of the patient with amyotrophic lateral sclerosis : Drug, nutritional, and respiratory therapies (an evidence-based review) : Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009 ; 73 (15) : 1218-1226.
 
16) Plowman EK, et al. Discriminant ability of the Eating Assessment Tool-10 to detect aspiration in individuals with amyotrophic lateral sclerosis. Neurogastroenterol Motil 2016 ; 28 : 85-90.
PubMed
17) Wills AM, et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis : A randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014 ; 383 (9934) : 2065-2072.
PubMed
18) 清水俊夫ほか. 呼吸器補助・経管栄養下のALS患者の必要エネルギー量の検討. 臨床神経学 1991 ; 31 (3) : 255-259.
 
Volkert D, et al. ESPEN guidelines on nutrition in dementia. Clin Nutr 2015 ; 34 (6) : 1052-1073.
PubMed
P.157 掲載の参考文献
1) Sherrington CS. Remarks on some aspects of reflex inhibition. Proc R Soc Lond 1925 ; 97 (686) : 519-545.
 
2) Brown HR, et al. Diseases of the nerve and motor unit. In : Kandel ER, et al (editors). Principles of Neural Science, 5th edition. New York : McGraw-Hill Professional ; 2014. pp. 307-336.
 
3) Voet NB, et al. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev 2013 ; 7 : CD003907.
 
4) Voss DE, et al. Proprioceptive Neuromuscular Fascilitation : Patterns and Techniques. New York : Harper & Row ; 1956.
 
5) Johnson EW, Braddom R. Over-work weakness in facioscapulohuumeral muscular dystrophy. Arch Phys Med Rehabil 1971 ; 52 (7) : 333-336.
PubMed
6) Gianola S, et al. Efficacy of muscle exercise in patients with muscular dystrophy : A systematic review showing a missed opportunity to improve outcomes. PloS ONE 2013 ; 8 (6) : e65414.
PubMed
7) Dal Bello-Haas V, Florence JM. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev 2013 ; 5 : CD005229.
PubMed
8) Wernig A, et al. Laufband (treadmil) therapy in incomplete paraplegia and tetraplegia J Neurotrauma 1999 ; 16 (8) : 719-726.
 
9) Mehrholz J, et al. Treadmill training for patients with Parkinson's disease. Cochrane Database Syst Rev 2015 (9) ; CD007830.
 
10) Sankai Y, et al (editors). Cybernics : Fusion of Human, Machine and Information Systems. Tokyo : Springer Japan ; 2014.
 
11) CYBERDYNE. HAL(R) 医療用下肢タイプ添付文書. 2016年2月15日作成 (第1版). https://www.cyberdyne.jp/products/pdf/HT010910A-U01_R1.pdf
 
12) Wall A, et al. Clinical application of the Hybrid Assistive Limb (HAL) for gait training-a systematic review. Front Syst Neurosci 2015 ; 9 : 48.
PubMed
13) 中島孝. ロボットスーツによる神経機能回復メカニズム. Clinical Neuroscience 2016 ; 34 (8) : 936-937.
 
14) CYBERDYNE. HAL(R) 医療用下肢タイプ 適正使用ガイド, 第2版. 2016年5月6日発行. https://www.cyberdyne.jp/products/pdf/HT010911A-U01_R2.pdf
 
15) CYBERDYNE. HAL(R) 自立支援用 (単関節タイプ). 2016. http://www.cyberdyne.jp/products/SingleJoint.html
 
P.165 掲載の参考文献
1) Ogden R, Franz SI. On cerebral motor control : The recovery from experimentally produced hemiplegia. Psychobiology 1917 ; 1 : 33-47.
 
2) Knapp HD, et al. Movements in monkeys with deafferented forelimbs. Exp Neurol 1963 ; 7 : 305-315.
PubMed
3) Ostendorf C, Wolf S. Effect of forced use of the upper extremity of a hemiplegic patient on changes in function : A single-case design. Phys Ther 1981 ; 61 : 1022-1028.
PubMed
4) Wolf SL, et al. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke : The EXCITE randomized clinical trial. JAMA 2006 ; 296 (17) : 2095-2104.
 
5) Liepert J, et al. Treatment-induced cortical reorganization after stroke in humans. Stroke 2000 ; 31 : 1210-1216.
PubMed
6) Kononen M, et al. Increased perfusion in motor areas after constraint-induced movement therapy in chronic stroke : A single-photon emission computerized tomography study. J Cereb Blood Flow Metab 2005 ; 25 (12) : 1668-1674.
PubMed
7) Gauthier LV, et al. Remodeling the brain : Plastic structural brain changes produced by different motor therapies after stroke. Stroke 2008 ; 39 : 1520-1525.
PubMed
8) Winstein CJ, et al. Guidelines for Adult Stroke Rehabilitation and Recovery : A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association (vol 47, pg 98, 2016). Stroke 2017 ; 48 (2) : e78.
 
9) 日本脳卒中学会 脳卒中ガイドライン委員会 (編). 脳卒中治療ガイドライン 2015. 東京 : 協和企画 ; 2015.
 
10) 道免和久, 竹林崇. Constraint-induced movement therapy (CI療法) -最近の知見. リハビリテーション医学 2013 ; 50 (9) : 712-717.
Medical*Online
11) Hosomi M, et al. A modified method for constraint-induced movement therapy : A supervised self-training protocol. J Stroke Cerebrovasc Dis 2012 ; 21 (8) : 767-775.
PubMed
12) Taub E, et al. Method for enhancing real-world use of a more affected arm in chronic stroke : Transfer package of constraint-induced movement therapy. Stroke 2013 ; 44 (5) : 1383-1388.
 
13) Takebayashi T, et al. A 6-month follow-up after constraint-induced movement therapy with and without transfer package for patients with hemiparesis after stroke : A pilot quasi-randomized controlled trial. Clin Rehabil 2013 ; 27 (5) : 418-426.
PubMed
14) Takebayashi T, et al. Therapeutic synergism in the treatment of post-stroke arm paresis utilizing botulinum toxin, robotic therapy, and constraint-induced movement therapy. PM R 2014 ; 6 (11) : 1054-1058.
PubMed
15) Mark VW, et al. Constraint-induced movement therapy for the lower extremities in multiple sclerosis : Case series with 4-year follow-up. Arch Phys Med Rehabil 2013 ; 94 : 753-760.
PubMed
道免和久 (編). ニューロリハビリテーション. 東京 : 医学書院 ; 2015.
 
Takebayashi T, et al. A one-year follow-up after modified constraint-induced movement therapy for chronic stroke patients with paretic arm : A prospective case series study. Top Stroke Rehabil 2015 ; 22 (1) : 18-25.
 
P.173 掲載の参考文献
1) 厚生労働省. 理学療法士・作業療法士の需給推計方法について. http://www.mhlw.go.jp/stf/shingi/other-isei.html?tid=348780
 
2) 日本言語聴覚士協会. https://www.jaslht.or.jp/
 
3) 日本理学療法士協会. http://www.japanpt.or.jp/
 
4) 日本作業療法士協会. http://www.jaot.or.jp/
 
5) 内山靖 (編). 理学療法学概説. 奈良勲 (監修), 標準理学療法学 専門分野. 東京 : 医学書院 ; 2014.
 
6) Hatem SM, et al. Rehabilitation of motor function after stroke : A multiple systematic review focused on techniques to stimulate upper extremity recovery. Front Hum Neurosci 2016 ; 10 : 442.
PubMed
7) 板場英行. 運動療法とは何か. 吉尾雅春ほか (編), 標準理学療法学 専門分野, 運動療法学 総論, 第3版. 東京 : 医学書院 ; 2010, pp. 8-18.
 
8) 星文彦. 理学療法の対象と治療手段. 奈良勲 (編著), 理学療法概論, 第6版. 東京 : 医歯薬出版 ; 2013, pp. 75-134.
 
9) 日本作業療法士協会. 作業療法ガイドライン実践指針 (2013年度版), 2014. http://www.jaot.or.jp/wp-content/uploads/2015/10/OTguideline2013-practice.pdf
 
10) 厚生労働省医政局長. 医療スタッフの協働・連携によるチーム医療の推進について. 医政発0430第1号. 2010年4月30日.
 
11) 日本理学療法士協会, ガイドライン特別委員会 理学療法診療ガイドライン部会. 理学療法診療ガイドライン, 第1版. 2011. 「ダイジェスト版」http://jspt.japanpt.or.jp/guideline/
 
12) 石合純夫, 正門由久. 専門医としてリハビリテーション処方はどうするべきなのか. Jpn J Rehabil Med 2010 ; 47 : 449-462.
 
13) de Vries NM, et al. Physiotherapy and occupational therapy and mild to moderate Parkinson disease. JAMA Neurol 2016 ; 73 : 893-894.
PubMed
14) Tomlinson CL, et al. Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev 2013 ; 10 : CD002817.
 
15) 堀場充哉. パーキンソン病. 網本和ほか (編), 今日の理学療法指針. 東京 : 医学書院 ; 2015, pp252-258.
 
16) Dixon L, et al. Occupational therapy for patients with Parkinson's disease. Cochrane Database Syst Rev 2007 ; (3) : CD002813.
PubMed
17) Sturkenboom IH, et al. OTiP study group. Efficacy of occupational therapy for patients with Parkinson's disease : A randomised controlled trial. Lancet Neurol 2014 ; 13 : 557-566.
 
18) 望月久. 脊髄小脳変性症. 網本和ほか (編), 今日の理学療法指針. 東京 : 医学書院 ; 2015, pp. 259-263.
 
19) 山口普己. 脊髄小脳変性症. 澤俊二 (編), 作業療法士 イエロー・ノート 専門編, 第2版. 東京 : メジカルビュー社 ; 2013, pp. 601-602.
 
20) 牧田光代. 地域理学療法学. 内山靖 (編), 標準理学療法学 専門分野, 理学療法学概説. 東京 : 医学書院 ; 2014, pp. 193-199.
 
福井圀彦ほか (編). 脳卒中最前線-急性期の診断からリハビリテーションまで, 第4版. 東京 : 医歯薬出版 ; 2009.
 
小森哲夫 (監修), 田中勇次郎ほか (編). 神経難病領域のリハビリテーション実践アプローチ. 東京 : メジカルビュー社 ; 2015.
 
P.180 掲載の参考文献
1) 平山惠造. 神経症候学 改定第二版 I. 東京 : 文光堂 ; 2006, pp. 178-208.
 
2) 日本脳卒中学会 脳卒中ガイドライン委員会 (編). 脳卒中治療ガイドライン 2015. 東京 : 協和企画 ; 2015.
 
3) Robey RR. A meta-analysis of clinical outcomes in the treatment of aphasia. J Speech Lang Hear Res 1998 ; 41 : 172-187.
PubMed
4) Brady MC, et al. Speech and language therapy for aphasia following stroke. Cochrane Database Syst Rev 2012 ; (5) : CD000425.
PubMed
5) 三村將ほか. わが国における失語症言語治療の効果, メタアナリシス. 高次脳機能研究 2010 ; 30 : 42-52.
 
6) Pedersen PM, et al. Aphasia in acute stroke : Incidence, determinants, and recovery. Ann Neurol 1995 ; 38 : 659-666.
PubMed
7) Moss A, Nicholas M. Language rehabilitation in chronic aphasia and time postonset : A review of single-subject data. Stroke 2006 ; 37 : 3043-3051.
PubMed
8) Meinzer M, et al. Intensive language training in the rehabilitation of chronic aphasia : Efficient training by laypersons. J Int Neuropsychol Soc 2007 ; 13 (5) : 846-853.
PubMed
9) Ramig LO, et al. Intensive speech treatment for patients with Parkinson's disease : Short-and long-term comparison of two techniques. Neurology 1996 ; 47 : 1496-1504.
 
10) Narayana S, et al. Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis. Hum Brain Mapp 2010 ; 31 : 222-236.
PubMed
11) 鈴木淳一郎ほか. 脳深部刺激術後に生じた反復性発話異常に対してペーシングボードが有用であったパーキンソン病の1例. 臨床神経学 2013 ; 53 : 304-307.
 
12) 日本神経学会 (監修), 「筋萎縮性側索硬化症診療ガイドライン」作成委員会 (編). 筋萎縮性側索硬化症診療ガイドライン 2013. 東京 : 南江堂 ; 2013.
 
13) 西尾正輝. かつてわれわれはDysarthriaを「構音障害」と呼んでいた, といえる新たなる時代を迎えよう-小島氏への異論. 音声言語医学 2000 ; 41 : 73.
Medical*Online
Tomik B, Guiloff RJ, Dysarthria in amyotrophic lateral sclerosis : A review. Amyotroph Lateral Scler 2010 ; 11 : 4-15.
PubMed
Sapir S. Multiple factors are involved in the dysarthria associated with Parkinson's disease : A review with implications for clinical practice and research. J Speech Lang Hear Res 2014 ; 57 : 1330-1343.
 
Atkinson-Clement C, et al. Behavioral treatments for speech in Parkinson's disease : Meta-analyses and review of the literature. Neurodegener Dis Manag 2015 ; 5 : 233-248.
PubMed
Yorkston KMほか (著), 伊藤元信ほか (監訳), 藤原百合ほか (訳). 運動性発話障害の臨床-小児から成人まで. 東京 : インテルナ出版 ; 2004.
 
Lee Silverman Voice Treatment (LSVT(R)) とは (新潟リハビリテーション大学WEBサイト). http://nur.ac.jp/gs/lsvt/
 
LSVT Global WEBサイト. http://www.lsvtglobal.com/
 
P.186 掲載の参考文献
1) Fahn S, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004 ; 351 (24) : 2498-2508.
PubMed
2) Tomlinson CL, et al. Physiotherapy intervention in Parkinson's disease : Systematic review and meta-analysis. BMJ 2012 ; 345 : e5004.
PubMed
3) Boso M, et al. Neurophysiology and neurobiology of the musical experience. Func Neurol 2006 ; 21 (4) : 187-191.
 
4) Menon V, Levitin DJ. The rewards of music listening : Response and physiological connectivity of the mesolimbic system. Neuroimage 2005 ; 28 (1) : 175-184.
PubMed
5) Zhao K, et al. A systematic review and meta-analysis of music therapy for the older adults with depression. Int J Geriatr Psychiatry 2016 ; 31 : 1188-1198.
 
6) Chang YS, et al. The efficacy of music therapy for people with dementia : A meta-analysis of randomised controlled trials. J Clin Nurs 2015 ; 24 (23-24) : 3425-3440.
 
7) Fancourt D, et al. The psychoneuroimmunological effects of music : A systematic review and a new model. Brain Behav Immun 2014 ; 36 : 15-26.
 
8) Satoh M, Kuzuhara S. Training in mental singing while walking improves gait disturbance in Parkinson's disease patients. Eur Neurol 2008 ; 60 (5) : 237-243.
PubMed
9) Cancela J, et al. Designing auditory cues for Parkinson's disease gait rehabilitation. Conf Proc IEEE Eng Med Biol Soc 2014 ; 2014 : 5852-5855.
 
10) Pacchetti C, et al. Active music therapy in Parkinson's disease : An integrative method for motor and emotional rehabilitation. Psychosom Med 2000 ; 62 (3) : 386-393.
PubMed
11) Brown LA, et al. Obstacle crossing among people with Parkinson disease is influenced by concurrent music. J Rehabil Res Dev 2010 ; 47 (3) : 225-231.
 
12) 林明人. パーキンソン病に対する音楽療法. Monthly Book Medical Rehabilitation 2007 (76) : 71-76.
 
13) El Sharkawi A, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT) : A pilot study. J Neurol Neurosurg Psychiatry 2002 ; 72 (1) : 31-36.
 
14) Guzman-Garcia A, et al. Dancing as a psychosocial intervention in care homes : A systematic review of the literature. Int J Geriat Psychiatry 2013 ; 28 (9) : 914-924.
 
15) Pan XG, et al. Effects of Tai Chi exercise on blood pressure and plasma levels of nitric oxide, carbon monoxide and hydrogen sulfide in real-world patients with essential hypertension. Clin Exp Hypertens 2015 ; 37 (1) : 8-14.
 
16) Rios Romenets S, et al. Tango for treatment of motor and non-motor manifestations in Parkinson's disease : A randomized control study. Complement Ther Med 2015 ; 23 (2) : 175-184.
PubMed
17) Podsiadlo D, Richardson S. The timed "Up & Go" : A test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991 ; 39 (2) : 142-148.
 
P.193 掲載の参考文献
1) Nudo RJ, et al. Neural substrates for the effects of rehabilitative training on motor recovery after ischemic infarct. Science 1996 ; 272 (5269) : 1791-1794.
PubMed
2) Weiller C, et al. Individual patterns of functional reorganization in the human cerebral cortex after capsular infarction. Ann Neurol 1993 ; 33 : 181-189.
PubMed
3) Miyai I, et al. Premotor cortex is involved in restoration of gait in stroke. Ann Neurol 2002 ; 52 : 188-194.
PubMed
4) Ward NS, et al. Neural correlates of motor recovery after stroke : A longitudinal fMRI study. Brain 2003 ; 126 : 2476-2496.
PubMed
5) Miyai I, et al. Longitudinal optical imaging study for locomotor recovery after stroke. Stroke 2003 ; 34 : 2866-2870.
PubMed
6) Grefkes C, Fink GR. Connectivity-based approaches in stroke and recovery of function. Lancet Neurol 2014 ; 13 : 206-216.
PubMed
7) Carrera E, Tononi G. Diaschisis : Past, present, future. Brain 2014 ; 137 : 2408-2422.
PubMed
8) Ruber T, et al. Compensatory role of the cortico-rubro-spinal tract in motor recovery after stroke. Neurology 2012 ; 79 : 515-522.
PubMed
9) Ishida A, et al. Causal link between the cortico-rubral pathway and functional recovery through forced impaired limb use in rats with stroke. J Neurosci 2016 ; 36 : 455-467.
PubMed
10) Langhorne P, et al. Motor recovery after stroke : A systematic review. Lancet Neurol 2009 ; 8 : 741-754.
PubMed
11) Wolf SL, et al. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke : The EXCITE randomized clinical trial. JAMA 2006 ; 296 : 2095-2104.
 
12) Lo AC, et al. Robot-assisted therapy for long-term upper-limb impairment after stroke. N Engl J Med 2010 ; 362 : 1772-1783.
PubMed
13) Duncan PW, et al. Body-weight-supported treadmill rehabilitation after stroke. N Engl J Med 2011 ; 364 : 2026-2036.
PubMed
14) Ietswaart M, et al. Mental practice with motor imagery in stroke recovery : Randomized controlled trial of efficacy. Brain 2011 ; 134 : 1373-1386.
PubMed
15) Winstein CJ, et al. Interdisciplinary Comprehensive Arm Rehabilitation Evaluation Investigative Team. Effect of a Task-Oriented Rehabilitation Program on Upper Extremity Recovery Following Motor Stroke : The ICARE Randomized Clinical Trial. JAMA 2016 ; 315 (6) : 571-581.
PubMed
16) Hatakenaka M, et al. Impaired motor learning by a pursuit rotor test reduces functional outcomes during rehabilitation of poststroke ataxia, Neurorehabil Neural Repair 2012 ; 26 : 293-300.
PubMed
17) Hogan N, et al. Motions or muscles? Some behavioral factors underlying robotic assistance of motor recovery. J Rehabil Res Dev 2006 ; 43 (5) : 605-618.
 
18) Dobkin BH, et al. International randomized clinical trial, stroke inpatient rehabilitation with reinforcement of walking speed (SIRROWS), improves outcomes. Neurorehabil Neural Repair 2010 ; 24 (3) : 235-242.
PubMed
19) Han CE, et al. Stroke rehabilitation reaches a threshold. PLoS Computational Biology 2008 ; 4 (8) : e1000133.
PubMed
20) Lefaucheur JP, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 2014 ; 125 (11) : 2150-2206.
PubMed
21) Mukaino M, et al. Efficacy of brain-computer interface-driven neuromuscular electrical stimulation for chronic paresis after stroke. J Rehabil Med 2014 ; 46 : 378-382.
PubMed
22) Mihara M, et al. Near-infrared spectroscopy-mediated neurofeedback enhances efficacy of motor imagery-based training in poststroke victims : A pilot study. Stroke 2013 ; 44 : 1091-1098.
PubMed
23) Chollet F, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME) : A randomised placebo-controlled trial. Lancet Neurology 2011 ; 10 (2) : 123-130.
PubMed
24) Honmou O, et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 2011 ; 134 (Pt 6) : 1790-1807.
 
25) Steinberg GK, et al. Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke : A Phase 1/2a Study. Stroke 2016 ; 47 (7) : 1817-1824.
PubMed
26) Miyai I, et al. Results of new policies for inpatient rehabilitation coverage in Japan. Neurorehabil Neural Repair 2011 ; 25 (6) : 540-547.
PubMed
Cheeran B, et al. The future of restorative neurosciences in stroke : Driving the translational research pipeline from basic science to rehabilitation of people after stroke. Neurorehabil Neural Repair 2009 ; 23 (2) : 97-107.
PubMed
P.200 掲載の参考文献
1) Forbes D, et al. Exercise programs for people with dementia. Cochrane Database Syst Rev 2013 ; 12 : CD006489.
PubMed
2) Forbes D, et al. Exercise programs for people with dementia. Cochrane Database Syst Rev 2015 ; 4 : CD006489.
PubMed
3) Olazaran J, et al. Nonpharmacological therapies in Alzheimer's disease : A systematic review of efficacy. Dement Geriatr Cogn Disord 2010 ; 30 (2) : 161-178.
PubMed
4) NICE guideline. Dementia, disability and frailty in later life-mid-life approaches to delay or prevent onset. 2015. https://www.nice.org.uk/guidance/ng16.
 
5) Laurin D, et al. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol 2001 ; 58 (3) : 498-504.
PubMed
6) Larson EB, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006 ; 144 (2) : 73-81.
PubMed
7) Podewils LJ, et al. Physical activity, APOE genotype, and dementia risk : Findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 2005 ; 161 (7) : 639-651.
PubMed
8) Middleton LE, Yaffe K. Targets for the prevention of dementia. J Alzheimers Dis 2010 ; 20 (3) : 915-924.
PubMed
9) Erickson KI, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A 2011 ; 108 (7) : 3017-3022.
PubMed
10) Liu-Ambrose T, et al. Resistance training and executive functions : A 12-month randomized controlled trial. Arch Intern Med 2010 ; 170 (2) : 170-178.
PubMed
11) Suzuki T, et al. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. PLoS One 2013 : 8 (4) : e61483.
 
12) Lautenschlager NT. et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease : A randomized trial. JAMA 2008 ; 300 (9) : 1027-1037.
PubMed
13) Gates N, et al. The effect of exercise training on cognitive function in older adults with mild cognitive impairment : A meta-analysis of randomized controlled trials. Am J Geriatr Psychiatry 2013 ; 21 (11) : 1086-1097.
PubMed
14) Suzuki T, et al. Effects of multicomponent exercise on cognitive function in older adults with amnestic mild cognitive impairment : A randomized controlled trial. BMC Neurol 2012 ; 12 : 128.
PubMed
15) Strohle A, et al. Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment : A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials. Am J Geriatr Psychiatry 2015 ; 23 (12) : 1234-1249.
PubMed
16) Ngandu T, et al. A 2 year multidomain intervention of diet, exercise. cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER) : A randomised controlled trial. Lancet 2015 ; 385 (9984) : 2255-2263.
 
17) Cotman CW, et al. Exercise builds brain health : Key roles of growth factor cascades and inflammation. Trends Neurosci 2007 ; 30 (9) : 464-472.
 
18) Rolland Y, et al. Physical activity and Alzheimer's disease : From prevention to therapeutic perspectives. J Am Med Dir Assoc 2008 ; 9 (6) : 390-405.
PubMed
P.206 掲載の参考文献
1) WHO. WHO Definition of Palliative Care. http://www.who.int/cancer/palliative/definition/en/
PubMed
2) 清水哲郎. 臨床倫理の考え方. 臨床倫理学と医療人類学のフォーラム-緩和ケアの臨床現場を支えるために. 17/Apr/2010. http://www.l.u-tokyo.ac.jp/~shimizu/cleth-dls/1004cleth&pal.pdf
 
3) 厚生労働省. 中央社会保険医療協議会費用対効果評価専門部会第36回議事資料. http://www.mhlw.go.jp/stf/shingi2/0000144194.htm1
 
4) Bach JR, et al. Life satisfaction of individuals with Duchenne muscular dystrophy using long-term mechanical ventilator support. Am J Phys Med Rehab 1991 ; 70 (3) : 129-135.
 
5) 辻省次 (総編集), 西澤正豊 (編). アクチュアル 脳・神経疾患の臨床, すべてがわかる神経難病医療. 東京 : 中山書店 ; 2015.
 
6) Kitwood T. Dementia Reconsidered : The Person Comes First. Berkshire, UK : Open University Press ; 1997.
 
7) 厚生労働省. 人生の最終段階における医療の決定プロセスに関するガイドライン. 平成19年5月 (改訂 平成27年3月). http://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000078981.pdf
 
8) 日本神経学会 (監修). 筋萎縮性側索硬化症診療ガイドライン 2013. CQ3-1～3-11, 東京 : 南江堂 ; 2013, pp. 46-69.
 
9) 板井孝壱郎. 人工呼吸器療法の中止. 西澤正豊 (編), アクチュアル 脳・神経疾患の臨床, すべてがわかる神経難病医療. 東京 : 中山書店 ; 2015, pp. 355-361.
 
10) Oliver D, et al (editors). Palliative Care in Amyotrophic Lateral Sclerosis : From Diagnosis to Bereavement, 3rd edition. New York : Oxford University Press ; 2014.
 
11) WHO. Health legistlation at the down of the XXI century, International Digest of Health Legislation 1998 ; 49 (1) : 1-296. http://www.who.int/iris/bitstream/10665/63933/1/IDHL_1998_49_p1-296_Special_issue_eng.pdf?
 
12) 後明郁男ほか. 特集 がんだけじゃない! 緩和医療-近年話題となっている非がん領域の緩和医療を中心に. 治療 2013 ; 95 : 1267-1356.
 
13) 平原佐斗司 (編著). チャレンジ! 非がん疾患の緩和ケア. 東京 : 南山堂 ; 2011.
 
14) 厚生労働省. がん等における緩和ケアの更なる推進に関する検討会における議論の整理. http://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000153445.pdf
 
15) 荻野美恵子. 緩和ケアと看取り. 西澤正豊 (編), アクチュアル 脳・神経疾患の臨床, すべてがわかる神経難病医療. 東京 : 中山書店 ; 2015. pp. 145-152.
 
16) 宮川沙織, 荻野美恵子. ALSに対する緩和医療. 祖父江元 (編). アクチュアル 脳・神経疾患の臨床, すべてがわかるALS・運動ニューロン疾患. 東京 : 中山書店 ; 2013, pp. 306-313.
 
17) 成田有吾 (編著). 改訂版 神経難病在宅療養ハンドブック-よりよい緩和ケアの提供のために. 大阪 : メディカルレビュー ; 2016, pp71-98.
 
18) 森田達也, 木澤義之 (編). 緩和ケアレジデントマニュアル. 東京 : 医学書院 ; 2016, pp. 77-106.
 
19) 日本神経学会 (監修). 筋萎縮性側索硬化症診療ガイドライン 2013. CQ3-12「強オピオイド (モルヒネなど) はどのように使用するか」. 東京 : 南江堂 ; 2013. pp. 70-72.
 
WHO. Palliative Care. http://www.who.int/mediacentre/factsheets/fs402/en/
 
P.215 掲載の参考文献
1) Cortese I, et al. Evidence-based guideline update : Plasmapheresis in neurologic disorders : Report of the Therapeutics and Technology Assessment Subcolnmittee of the American Academy of Neurology. Neurology 2011 ; 76 : 294-300.
PubMed
2) Weiner HL, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989 ; 39 : 1143-1149.
PubMed
3) Watanabe S, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007 ; 13 : 128-132.
PubMed
4) Kleiter I, et al. Neuromyelitis optica : Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 2016 ; 79 : 206-216.
PubMed
5) Hughes RA, et al. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978 ; 2 : 750-753.
PubMed
6) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet 1997 ; 349 : 225-230.
PubMed
7) Kuitwaard K, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol 2009 ; 66 : 597-603.
PubMed
8) Walgaard C, et al. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 2011 ; 76 : 968-975.
PubMed
9) Van den Bergh PY, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. Eur J Neurol 2010 ; 17 : 356-363.
PubMed
10) Dyck PJ, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994 ; 36 : 838-845.
PubMed
11) Hughes RA, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study) : A randomised placebo-controlled trial. Lancet Neurol 2008 ; 7 : 136-144.
PubMed
12) Hughes R, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001 ; 50 : 195-201.
PubMed
13) Qureshi AI, Suri MF. Plasma exchange for treatment of myasthenia gravis : Pathophysiologic basis and clinical experience. Ther Apher 2000 ; 4 : 280-286.
PubMed
14) 加藤茉里ほか. 抗AChR抗体陽性重症筋無力症の急性増悪期治療-血液浄化療法と免疫グロブリン大量療法の比較. 神経治療学 2014 ; 31 : 37-42.
Medical*Online
15) 野村恭一ほか. 免疫吸着 (TR-350) 療法は自己抗体のIgGサブクラスにより除去能が異なる. 厚生労働科学研究費補助金難治性疾患克服研究事業, 免疫性神経疾患に関する調査研究班, 平成20年度総括・分担研究報告書, pp. 52-55.
 
16) Burns TM, et al. The MG Composite : A valid and reliable outcome measure for myasthenia gravis. Neurology 2010 ; 74 : 1434-1440.
PubMed
P.224 掲載の参考文献
1) Barker AT, et al. Non-invasive magnetic stimulation of human motor cortex. Lancet 1985 ; 1 (8437) : 1106-1107.
PubMed
2) 松本英之, 宇川義一. 経頭蓋磁気刺激の臨床応用および新しい刺激法. 計測と制御 2015 ; 54 : 100-105.
 
3) Pascual-Leone A, et al. Responses to rapid-rate transcranial magnetic stimulation of the human motor cortex. Brain 1994 ; 117 : 847-858.
PubMed
4) Chen R, et al. Depression of motor cortex excitability by low-frequency trarlscranial magnetic stimulation. Neurology 1997 ; 48 : 1398-1403.
PubMed
5) Lefaucheur JP, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 2014 ; 125 : 2150-2206.
 
6) Rossi S, et al. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 2009 ; 120 : 2008-2039.
PubMed
7) Fleming JJ, England PM. AMPA receptors and synaptic plasticity : A c hemist's perspective. Nat Chem Biol 2010 ; 6 : 89-97.
 
8) Ugawa Y. Motor cortical plasticity in basal ganglia disorders or movement disorders. Basal Ganglia 2012 : 2 : 119-121.
 
9) Yamanishi T, et al. Multicenter, randomized, sham-controlled study on the efficacy of magnetic stimulation for women with urgency urinary incontinence. Int J Urol 2014 ; 21 : 395-400.
 
10) Hamada M, et al. High-frequency rTMS over the supplementary motor area for treatment of Parkinson's disease. Mov Disord 2008 ; 23 : 1524-1531.
PubMed
11) Matsumoto H, Ugawa Y. Therapeutic effects of non-invasive brain stimulation for dystonia. Basal Ganglia 2016 ; 6 : 101-105.
 
12) Hosomi K, et al. Daily repetitive trarlscranial magnetic stimulation of primary motor cortex for neuropathic pain : A randomized, multicenter, double-blind, crossover, sham-controlled trial. Pain 2013 ; 154 : 1065-1072.
PubMed
13) 岡部慎吾, 宇川義一. 脊髄小脳変性症. 神経治療学 2006 ; 23 : 477-482.
Medical*Online
14) Huang YZ, et al. Theta burst stimulation of the human motor cortex. Neuron 2005 ; 45 : 201-206.
 
15) Hamada M, et al. Bidirectional long-term motor cortical plasticity and metaplasticity induced by quadripulse transcranial magnetic stimulation. J Physiol 2008 ; 586 : 3927-3947.
PubMed
16) 松本英之, 宇川義一. 磁気刺激法の安全性に関するガイドライン. 臨床神経生理学 2011 ; 39 : 34-45.
Medical*Online
Rossini PM, et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves : Basic principles and procedures for routine clinical and research application. An updated report from an I. F. C. N. Committee. Clin Neurophysiol 2015 ; 126 : 1071-1107.
 
Quartarone A, et al. Task-specific hand dystonia : Can too much plasticity be bad for you? Trends Neurosci 2006 ; 29 : 192-199.
PubMed
Karabanov A, et al. Consensus paper : Probing homeostatic plasticity of human cortex with non-invasive transcranial brain stimulation. Brain Stimul 2015 ; 8 : 442-454.
PubMed
P.230 掲載の参考文献
1) 本橋伸高. ECTマニュアル-科学的精神医学をめざして. 東京 : 医学書院 ; 2000.
 
2) Sienaert P. Based on a true story? The portrayal of ECT in international movies and television programs. Brain Stimul 2016 ; 9 : 882-891.
PubMed
3) 本橋伸高ほか. 電気けいれん療法 (ECT) 推奨事項 改訂版. 精神神経学雑誌 2013 ; 115 : 586-600,
 
4) Swartz CM, Nelson AI. Rational electroconvulsive therapy electrode placement. Psychiatry (Edgmont) 2005 ; 2 (7) : 37-43.
PubMed
5) Mankad MV, et al. Clinical Manual of Electroconvulsive Therapy. Washington DC : American Psychiatric Association Publishing ; 2010/本橋伸高ほか (監訳). パルス波ECTハンドブック. 東京 : 医学書院 ; 2012.
 
6) Kennedy R, et al. Electroconvulsive therapy in movement disorders : An update J Neuropsychiatry Clin Neurosci 2003 ; 15 : 407-421.
PubMed
7) Popeo D, Kelmer CH. ECT for Parkinson's disease. Med Hypotheses 2009 ; 73 : 468-469.
 
8) Andersen K, et al. A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena. Acta Neurol Scand 1987 ; 76 : 191-199.
 
9) Usui C, et al. Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiaty 2011 ; 35 : 1704-1708.
 
10) Acharya D, et al. Safety and utility of acute electroconvulsive therapy for agitation and aggression in dementia. Int J Geriatr Psychiatry 2015 ; 30 : 265-273.
PubMed
11) Burgut FT, Kelmer CH. Electroconvulsive therapy (ECT) for dementia with Lewy bodies. Med Hypotheses 2010 ; 75 : 139-140.
 
12) Steen K, et al. Electroconvulsive therapy in multiple sclerosis. Innov Clin Neurosci 2015 ; 12 : 28-30.
PubMed
13) Braakman HM, et al. Pearls & Oy-sters : Electroconvulsive therapy in anti-NMDA receptor encephalitis. Neurology 2010 ; 75 : e44-e46.
PubMed
14) Caplan G. Electrical convulsion therapy in the treatment of epilepsy. J Menti Sci 1946 ; 92 : 784-793.
 
15) Zeiler FA, et al. Electroconvulsive therapy for refractory status epilepticus : A systematic review. Seizure 2016 ; 35 : 23-32.
PubMed
16) Katus LE, Frucht SJ. Management of serotonin syndrome and neuroleptic malignant syndrome. Curr Treat Options Neurol 2016 ; 18 : 39.
PubMed
17) 高野晴成, 本橋伸高. 電気けいれん療法 (ECT) の作用機序の解明. 臨床精神医学 2013 : 42 : 459-465.
Medical*Online
P.240 掲載の参考文献
1) 日本呼吸器学会. 呼吸器の病気. H-02 呼吸不全. 慢性呼吸不全. http://www.jrs.or.jp/modules/citizen/index.php?content_id=37 (161022 accessed)
 
2) 日本神経学会 (監修), 「筋萎縮性側索硬化症診療ガイドライン」作成委員会 (編). 呼吸不全の早期診断はどうすればよいか. 筋萎縮性側索硬化症診療ガイドライン 2013, 東京 : 南江堂 ; 2013, pp. 118-119.
 
3) 日本神経学会 (監修), 「筋萎縮性側索硬化症診療ガイドライン」作成委員会 (編), どのように告知し, 病状を説明するか. 筋萎縮性側索硬化症診療ガイドライン 2013. 東京 : 南江堂 ; 2013, pp. 46-49.
 
4) 橋本司, 医療処置の選択に対する説明と施行のポイント. 呼吸機能低下に対して. 成田有吾 (編著), 改訂版 神経難病在宅療養ハンドブック-よりよい緩和ケア提供のために. 大阪 : メディカルレビュー ; 2016, pp. 4-69.
 
5) Miller RG, et al. Practice parameter : The care of the patient with amyotrophic lateral sclerosis (an evidence-based review) : Report of the Quality Standards Subcommittee of the American Academy of Neurology : ALS Practice Parameters Task Force. Neurology 1999 ; 52 : 1311-1323.
 
6) Miller RG, et al. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research. J Neurol Sci 1999 ; 169 : 2-12.
 
7) 木村文治. 筋萎縮性側索硬化症-人工呼吸器装着の背景因子と予後分析. 臨床神経学 2016 ; 56 : 241-247.
 
8) 伊藤恒ほか. 筋萎縮性側索硬化症に対する横隔膜ペーシング-安全性と有効性の短期評価. 神経治療学 2015 ; 32 : 501-505.
Medical*Online
9) 日本呼吸器学会NPPVガイドライン作成委員会 (編). 各論 B. 慢性呼吸不全. 5. 神経筋疾患. NPPV (非侵襲的陽圧換気療法) ガイドライン 改訂第2版. 東京 : 南江堂 ; 2015, pp. 136-142.
 
10) 日本呼吸器学会NPPVガイドライン作成委員会 (編). 総論. 4, 慢性呼吸不全におけるNPPVの導入方法. NPPV (非侵襲的陽圧換気療法) ガイドライン 改訂第2版. 東京 : 南江堂 ; 2015, pp. 19-26. http://fa.jrs.or.jp/guidelines/NPPVGL.pdf
 
11) 日本神経学会 (監修), 「筋萎縮性側索硬化症診療ガイドライン」作成委員会 (編). 呼吸機能障害に対するリハビリテーションはどのように行うか. 筋萎縮性側索硬化症診療ガイドライン 2013. 東京 : 南江堂 ; 2013, pp. 120-121.
 
12) 荻野美恵子ほか. 神経難病における苦痛症状とその対応. 成田有吾 (編著). 改訂版 神経難病在宅療養ハンドブック-よりよい緩和ケア提供のために. 大阪 : メディカルレビュー ; 2016, pp. 71-98.
 
日本神経学会 (監修). 「筋萎縮性側索硬化症診療ガイドライン」作成委員会 (編). 筋萎縮性側索硬化症診療ガイドライン 2013. 東京 : 南江堂 ; 2013.
 
成田有吾 (編著). 改訂版 神経難病在宅療養ハンドブック-よりよい緩和ケア提供のために. 大阪 : メディカルレビュー ; 2016.
 
P.251 掲載の参考文献
1) Deuschl G, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006 ; 355 (9) : 896-908.
PubMed
2) Castrioto A, et al. Ten-year outcome of subthalamic stimulation in Parkinson disease : A blinded evaluation. Arch Neurol 2011 ; 68 (12) : 1550-1556.
PubMed
3) Kupsch A, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006 ; 355 (19) : 1978-1990.
 
4) Andrews C, et al. Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes. J Neurol Neurosurg Psychiatry 2010 ; 81 (12) : 1383-1389.
PubMed
5) Benabid AL, et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991 ; 16 ; 337 (8738) : 403-406.
 
6) Sydow O, et al. Multicentre European study of thalamic stimulation in essential tremor : A six year follow up. J Neurol Neurosurg Psychiatry 2003 ; 74 (10) : 1387-1391.
PubMed
7) Binder DK, et al. Risk factors for hemorrhage during microelectrode-guided deep brain stimulator implantation for movement disorders. Neurosurgery 2005 ; 56 (4) : 722-732.
PubMed
8) Deep-Brain Stimulation for Parkinson's Disease Study Group, et al. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001 ; 345 (13) : 956-963.
PubMed
9) Schuepbach WM, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013 ; 368 (7) : 610-622.
PubMed
10) Weaver FM, et al. Randomized trial of deep brain stimulation for Parkinson disease : Thirty-six-month outcomes. Neurology 2012 ; 79 (1) : 55-65.
PubMed
11) Odekerken VJ, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study) : A randomised controlled trial. Lancet Neurol 2013 ; 12 (1) : 37-44.
PubMed
12) Spiegel EA, et al. Stereotaxic Apparatus for Operations on the Human Brain. Science 1947 ; 106 (2754) : 349-350.
PubMed
13) Benabid AL, et al. Acute and long-term efFects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact Funct Neurosurg 1994 ; 62 (1-4) : 76-84,
 
14) von Langsdorff D, et al. In vivo measurement of the frame-based application accuracy of the Neuromate neurosurgical robot. J Neurosurg 2015 ; 122 (1) : 191-194.
PubMed
15) Steigerwald F, et al. Directional deep brain stimulation of the subthalamic nucleus : A pilot study using a novel neurostimulation device. Mov Disord 2016 ; 31 (8) : 1240-1243.
PubMed
16) Elias WJ, et al. A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med 2013 ; 369 (7) : 640-648.
PubMed
17) Elias WJ, et al. A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor. N Engl J Med 2016 ; 375 (8) : 730-739.
PubMed
Laxton AW, et al. A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann Neurol 2010 ; 68 (4) : 521-534.
PubMed
Fisher R, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia 2010 ; 51 (5) : 899-908.
PubMed
P.261 掲載の参考文献
1) Karas PJ, et al. Deep brain stimulation : A mechanistic and clinical update. Neurosurg Focus 2013 ; 35 : E1.
PubMed
2) Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson' s disease. N Engl J Med 2001 ; 345 : 956-963.
PubMed
3) Charles PD, et al. Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 2002 ; 59 (6) : 932-934.
PubMed
4) Russmann H, et al. Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology 2004 ; 63 (10) : 1952-1954.
PubMed
5) Follett KA, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010 ; 362 : 2077-2091.
PubMed
6) Odekerken VJ, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study) : A randolnized controlled trial. Lancet Neurol 2013 ; 12 : 37-44.
PubMed
7) Kempster PA, et al. Relationships between age and late progression of Parkinson's disease : A clinico-pathological study. Brain 2010 ; 133 : 1755-1762.
PubMed
8) Kempster PA, et al. Patterns of levodopa response in Parkinson's disease : A clinico-pathological study. Brain 2007 ; 130 : 2123-2128.
PubMed
9) Schuepbach WM, et al. Neurostimulation for Parkinson's disease with early motor complications, N Engl J Med 2013 ; 368 : 610-622.
PubMed
10) Krack P, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003 ; 349 : 1925-1934.
PubMed
11) Merola A, et al. Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease : A different long-term outcome? J Neurol Neurosurg Psychiatry 2014 ; 85 : 552-559.
PubMed
12) Castrioto A, et al. Ten-year outcome of subthalamic stimulation in Parkinson disease : A blinded evaluation. Arch Neurol 2011 ; 68 : 1550-1556.
PubMed
13) Lilleen g B, et al. Progression and survival in Parkinson's disease with subthalamic nucleus stimulation. Acta Neurol Scand 2014 ; 130 : 292-298.
 
14) Ngoga D, et al. Deep brain stimulation improves survival in severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2014 ; 85 : 17-22.
PubMed
15) Witt K, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease : A randomised, multicentre study. Lancet Neurol 2008 ; 7 : 605-614.
PubMed
16) Fasano A. et al. Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain 2010 ; 133 : 2664-2676.
PubMed
17) Floden D, et al. Predicting quality of life outcomes after subthalamic nucleus deep brain stimulation. Neurology 2014 ; 83 : 1627-1633.
PubMed
18) Lewis CJ, et al. Parkinson's disease patients with subthalamic stimulation and carers judge quality of life differently. Parkinsonism Relat Disord 2014 ; 20 : 514-519.
PubMed
19) Baba T, et al. Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease : A 3 year longitudinal study. Brain 2012 ; 135 : 161-169.
PubMed
20) Amami P, et al. Impulse control behaviours in patients with Parkinson's disease after subthalamic deep brain stimulation : De novo cases and 3-year follow-up. J Neurol Neurosurg Psychiatry 2015 ; 86 : 562-564.
PubMed
21) Weaver FM, et al. Randomized trial of deep brain stimulation for Parkinson disease : Thirty-sixmonth outcomes. Neurology 2012 ; 79 (1) : 55-65.
 
22) Odekerken VJ, et al. GPi vs STN deep brain stimulation for Parkinson disease : Three-year follow-up. Neurology 2016 ; 86 (8) : 755-761.
PubMed
23) Sako W, et al. Which target is best for patients with Parkinson's disease? A meta-analysis of pallidal and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2014 ; 85 (9) : 982-986.
PubMed
24) Liu Y, et al. Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease, J Neurosurg 2014 ; 121 (3) : 709-718.
PubMed
25) Xie CL, et al. Effects of neurostimulation for advanced Parkinson's disease patients on motor symptoms : A multiple-treatments meta-analysis of randomized controlled trials. Sci Rep 2016 ; 6 : 25285.
PubMed
26) Sako W, et al. On-period unified Parkinson's disease rating scale before surgery correlates with differences in outcomes between pallidal and subthalamic stimulation : A meta-analysis. Neurol Sci 2016 ; 37 (1) : 135-137.
PubMed
27) Bonenfant J, et al. Pallidal stimulation in Parkinson's patients with contraindications to subthalamic target : A 3 years follow-up. Parkinsonism Relat Disord 2017 ; 34 : 20-25.
 
P.269 掲載の参考文献
1) Wiebe S, et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001 ; 345 (5) : 311-318.
 
2) Usami K et al. Scalp-recorded evoked potentials as a marker for afferent nerve impulse in clinical vagus nerve stimulation. Brain Stimul 2013 ; 6 (4) : 615-623.
PubMed
3) Kuba R, et al. Vagus nerve stimulation : Longitudinal follow-up of patients treated for 5 years. Seizure 2009 ; 18 (4) : 269-274.
PubMed
4) Elliott RE, et al. Vagus nerve stimulation in 436 consecutive patients with treatment-resistant epilepsy : Long-term outcomes and predictors of response. Elpilepsy Behav 2011 ; 20 (1) : 57-63.
PubMed
5) 川合謙介. 難治性てんかんに対する迷走神経刺激療法-使用成績調査 中間成績報告から. VNS Advancement for Epilepsy 2014. Vol. 1.
 
6) Ben-Menachem E. Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol 2002 ; 1 (8) : 477-482.
PubMed
7) Morris GL, 3rd, Mueller WM. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology 1999 ; 53 (8) : 1731-1735.
 
8) de Jonge JC, et al. Safety of a dedicated brain MRI protocol in patients with a vagus nerve stimulator. Epilepsia 2014 ; 55 (11) : e112-115.
PubMed
9) Couch JD, et al. Long-term expectations of vagus nerve stimulation : A look at battery replacement and revision surgery. Neurosurgery 2016 ; 78 (1) : 42-46.
 
P.276 掲載の参考文献
1) 桑山直也. 脳動脈瘤・頚動脈狭窄症に対する脳血管内治療. 脳外誌 2010 ; 19 : 41-46.
 
2) Kaku Y, et al. Factors predictive of cerebral hyperperfusion after carotid angioplasty and stent placement. AJNR Am J Neuroradiol 2004 ; 25 : 1403-1408.
PubMed
3) Yoshimura S, et al. High-intensity signal on time-of-flight magnetic resonance angiography indicates carotid plaques at high risk for cerebral embolism during stenting. Stroke 2011 ; 42 : 3132-3137.
PubMed
4) Yuan C, et al. MRI of atherosclerosis in clinical trials. NMR Biomed 2006 ; 19 : 636-654.
 
5) 吉村紳一ほか. 脳血管内治療診療指針. 7. 頚動脈狭窄症. JNET 2009 ; 3 (Suppl 1) : 56-65.
 
6) Bijuklic K, et al. The PROFI study (Prevention of Cerebral Embolization by Proximal Balloon Occlusion Compared to Filter Protection During Carotid Artery Stenting) : A prospective randomized trial. J Am Coll Cardiol 2012 ; 59 : 1383-1389.
 
7) Yoshimura S, et al. Efficacy of endovascular treatment for acute cerebral large-vessel occlusion : Analysis of nationwide prospective registry. J Stroke Cerebrovasc Dis 2014 ; 23 : 1183-1190.
PubMed
8) Broderick JP, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013 ; 368 : 893-903.
PubMed
9) Kidwell CS, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013 ; 368 : 914-923.
PubMed
10) Ciccone A, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013 ; 368 : 904-913.
PubMed
11) Yoshimura S, et al. Endovascular treatment of acute ischemic stroke : Honolulu shock and thereafter. J Stroke Cerebrovasc Dis 2014 ; 23 : e295-e298.
PubMed
12) Berkhemer OA, et al. A randomized trial of intraarterial treatment for acute ischemic stroke, N Engl J Med 2015 ; 372 : 11-20.
PubMed
13) Goyal M, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015 ; 372 : 1019-1030.
PubMed
14) Campbell BC, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015 ; 372 : 1009-1018.
PubMed
15) Saver JL, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015 ; 372 : 2285-2295.
PubMed
16) Jovin TG, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015 ; 372 : 2296-2306.
PubMed
17) Prabhakaran S, et al. Acute stroke intervention : A systematic review. JAMA 2015 ; 313 : 1451-1462.
PubMed
18) Powers WJ, et al. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment : A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2015 ; 46 ; 3020-3035.
PubMed
19) UCAS Japan Investigators. The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med 2012 ; 28 ; 366 : 2474-2482.
 
20) Lawton M, Spetzler RF. Surgical strategies for giant intracranial aneurysms. Acta Neurochir Supppl 1999 ; 72 ; 141-156.
 
21) Miyamoto S, et al. Successful obliteration and shrinkage of giant partially thrombosed basilar artery aneurysms through a tailored flow reduction strategy with bypass surgery. J Neurosurg 2011 ; 114 : 1028-1036.
PubMed
22) Piotin M, et al. Stent-assisted coiling of intracranial aneurysms : Clinical and angiographic results in 216 consecutive aneurysms. Stroke 2010 ; 41 : 110-115.
PubMed
23) Tateshima S. Treatment of Intracranial Aneurysm with Pipeline Flow Diversion Stent. No Shinkei Geka 2015 ; 43 : 775-785.
PubMed
24) Nelson PK, et al. The pipeline embolization device for the intracranial treatment of aneurysms trial. AJNR Am J Neuroradiol 2011 ; 32 : 34-40.
PubMed
25) Becske T, et al. Pipeline for uncoilable or failed aneurysms : Results from a multicenter clinical trial. Radiology 2013 ; 267 : 858-868.
 
26) Kallmes DF, et al. International retrospective study of the pipeline embolization device : A multicenter aneurysm treatment study. AJNR Am J Neuroradiol 2015 ; 36 : 108-115.
PubMed

II. 今後の治療法への展開

P.287 掲載の参考文献
1) Choong CJ, et al. Gene therapy for neurological disorders. Expert Opin Biol Ther 2016 ; 16 : 143-159.
PubMed
2) Christine CW, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009 ; 73 : 1662-1669.
PubMed
3) Muramatsu S, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 2010 ; 18 : 1731-1735.
PubMed
4) Mittermeyer G, et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 2012 ; 23 : 377-381.
PubMed
5) Palfi S, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease : A dose escalation, open-label, phase 1/2 trial. Lancet 2014 ; 383 : 1138-1146.
PubMed
6) LeWitt PA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease : A double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011 ; 10 : 309-319.
PubMed
7) Marks WJ Jr, et al. Gene delivery of AAV2-neurturin for Parkinson's disease : A double-blind, randomised, controlled trial. Lancet Neurol 2010 ; 9 : 1164-1172.
PubMed
8) Hasegawa K, et al. Promotion of mitochondrial biogenesis by necdin protects neurons against mitochondrial insults. Nat Commun 2016 ; 7 : 10943.
PubMed
9) Iwata N, et al. Presynaptic localization of neprilysin contributes to ef6cient clearance of amyloid-beta peptide in mouse brain. J Neurosci 2004 ; 24 : 991-998.
 
10) Nishiyama A, et al. Recombinant adeno-associated virus type 8-mediated extensive therapeutic gene delivery into skeletal muscle of alpha-sarcoglycan-deficient mice. Hum Gene Ther 2008 ; 19 : 719-730.
 
11) Ohshirna S, et al. Transduction ethciency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol Ther 2009 ; 17 : 73-80.
 
12) Hayashita-Kinoh H, et al. Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance. Mol Ther 2015 ; 23 : 627-637.
PubMed
13) 山下雄也, 郭伸. 孤発性ALS運動ニューロンにみられるRNA編集低下とTDP-43病理の分子連関メカニズム. 医学のあゆみ 2013 ; 247 : 412-420.
Medical*Online
14) Yamashita T, et al. Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons. EMBO Mol Med 2013 ; 5 : 1710-1719.
 
P.295 掲載の参考文献
1) Pizzorno MC, et al. trans-activation and autoregulation of gene expression by the immediate-early region 2 gene products of human cytomegalovirus. J Virol 1988 ; 62 (4) : 1167-1179.
PubMed
2) Ng EW, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006 ; 5 (2) : 123-132.
PubMed
3) Kastelein JJ, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006 ; 114 (16) : 1729-1735.
PubMed
4) Hua Y, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011 ; 478 (7367) : 123-126.
PubMed
5) Zanetta C, et al. Molecular therapeutic strategies for spinal muscular atrophies : Current and future clinical trials. Clin Ther 2014 ; 36 (1) : 128-140.
PubMed
6) Takeshima Y, et al. Modulation of in vitro splicing of the upstream intron by modifying an intraexon sequence which is deleted from the dystrophin gene in dystrophin Kobe. J Clin Invest 1995 ; 95 (2) : 515-520.
 
7) Sud R, et al. Antisense-mediated Exon Skipping Decreases Tau Protein Expression : A Potential Therapy For Tauopathies. Mol Ther Nucleic Acids 2014 ; 3 : e180.
PubMed
8) Bennett CF, Swayze EE. RNA targeting therapeutics : Molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010 ; 50 : 259-293.
PubMed
9) Monia BP, et al. Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 1993 ; 268 (19) : 14514-14522.
 
10) Teplova M, et al. Structural origins of the exonuclease resistance of a zwitterionic RNA. Proc Natl Acad Sci U S A 1999 ; 96 (25) : 14240-14245.
PubMed
11) Cerritelli SM, Crouch RJ. Ribonuclease H : The enzymes in eukaryotes. FEBS J 2009 ; 276 (6) : 1494-1505.
PubMed
12) Elbashir SM, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001 ; 411 (6836) : 494-498.
PubMed
13) Coelho T, et al. Safety and ethcacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013 ; 369 (9) : 819-829.
PubMed
14) BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa(TM) (drisapersen) in Europe.
 
15) Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51(TM) (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51. http://investorrelations.sarepta.com/phoenix.zhtml?c=64231&p=irol-newsArticle&ID=2204492.
 
16) デュシェンヌ型筋ジストロフィー治療剤NS-065の第I/II相臨床試験開始についてのお知らせ. http://www.nippon-shinyaku.co.jp/company_profile/news.php?id=2832.
 
17) デュシェンヌ型筋ジストロフィー治療剤「NS-065」の米国での前期第II相臨床試験開始についてのお知らせ. http://www.nippon-shinyaku.co.jp/company_profile/news.php?id=2918,
 
18) デュシェンヌ型筋ジストロフィー治療剤の国内臨床試験開始について. http://www.daiichisankyo.co.jp/news/detail/006411.html.
 
19) Miller TM, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis : A phase 1, randomised, first-in-man study. Lancet Neurol 2013 ; 12 (5) : 435-442.
PubMed
20) Limmroth V, et al ; ATL 1102 Study Group. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. Neurology 2014 ; 83 (20) : 1780-1788.
 
P.307 掲載の参考文献
1) Lane EL, Winkler C. L-DOPA- and graft-induced dyskinesia following transplantation. Prog Brain Res 2012 ; 200 : 143-168.
 
2) Olanow CW, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. J Ann Neurol 2003 ; 54 : 403-414.
 
3) Freed CR, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001 ; 344 : 710-719.
PubMed
4) Li JY, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008 ; 14 : 501-503.
PubMed
5) Kordower JH, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008 ; 14 : 504-506.
PubMed
6) Hansen C, et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011 ; 121 : 715-725.
 
7) Angot E, et al. Are synucleinopathies prion-like disorders? Lancet Neurol 2010 ; 9 : 1128-1138.
PubMed
8) Selden NR, et al. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr 2013 ; 11 : 643-652.
PubMed
9) Gupta N, et al. Neural stem cell engraftment and myelination in the human brain. Sci Transl Med 2012 ; 4 : 155ra137.
PubMed
10) Kalladka D, et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES) : A phase 1, first-in-man study. Lancet 2016 ; 388 : 787-796.
PubMed
11) Thomsen GM, et al. The past, present and future of stem cell clinical trials for ALS. Exp Neurol 2014 ; 262 Pt B : 127-137.
 
12) Mazzini L, et al. Human neural stem cell transplantation in ALS : Initial results from a phase I trial. J Transl Med 2015 ; 13 : 17.
PubMed
13) Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006 ; 126 : 663-676.
PubMed
14) Okita K, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods 2011 ; 8 : 409-412.
 
15) Kim JH, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002 ; 418 : 50-56.
 
16) Chambers SM, et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009 ; 27 : 275-280.
PubMed
17) Morizane A, et al. Neural induction with a dopaminergic phenotype from human pluripotent stem cells through a feeder-free floating aggregation culture. Methods Mol Biol 2013 ; 1018 : 11-19.
PubMed
18) Doi D, et al. Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease. Stem Cells 2012 ; 30 : 935-945.
 
19) Kikuchi T, et al. Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of Parkinson's disease. J Parkinsons Dis 2011 ; 1 : 395-412.
PubMed
20) Doi D, et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports 2014 ; 2 : 337-350.
PubMed
21) Trounson A, McDonald C. Stem cell therapies in clinical trials : Progress and challenges. Cell Stem Cell 2015 ; 17 : 11-22.
PubMed
22) Kimbrel EA, Lanza R. Current status of pluripotent stem cells : Moving the first therapies to the clinic. Nat Rev Drug Discov 2015 ; 14 : 681-692.
 
23) Vierbuchen T, et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010 ; 463 (7284) : 1035-1041.
PubMed
Barker RA, et al. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lance tNeurol 2013 ; 12 : 84-91.
 
Trounson A, McDonald C. Stem cell therapies in clinical trials: Progress and challenges. Cell Stem Cell 2015 ; 17 : 11-22.
PubMed
P.320 掲載の参考文献
1) ICH-M4 新医薬品の製造又は輸入の承認申請に際し承認申請書に添付すべき資料の作成要領について 別紙 1. https://www.pmda.go.jp/files/000156304.pdf
 
2) 水島徹. ドラッグ・リポジショニング. 日本口腔科学会雑誌 2015 ; 64 : 241-253.
Medical*Online
3) 小室美子. 神経疾患における最近の審査と国際共同治験の現状. 神経治療 2016 ; 33 : 268-272.
Medical*Online
4) 医薬品医療機器総合機構. ガイダンス・ガイドライン. https://www.pmda.go.jp/rs-std-jp/standards-development/guidance-guideline/0001.html
 
5) 厚生労働省. 薬事法等の一部を改正する法律について. http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000045726.html.
 
6) 嶽北和宏. 第14回日本再生医療学会総会シンポジウム 8「改正薬事法下における再生医療等製品の開発戦略とPMDAの果たすべき役割」再生医療等製品 : 条件及び期限付承認等の新たな制度的枠組みについて. 再生医療 2015 ; 14 : 52-56.
 
7) 厚生労働省. 先駆けパッケージ戦略-革新的医薬品等の実用化促進. http://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/topics/tp140729-01.html
 
8) 医薬品医療機器総合機構. 人道的見地から実施される治験について. https://www.pmda.go.jp/review-services/trials/0016.html
 
9) CDISC. Standards. http://www.cdisc.org/standards/foundational
PubMed
10) 厚生労働省医薬食品局. 医薬品・医療機器等安全性情報 No. 321.
Medical*Online
11) 医薬品医療機器総合機構. MIHARI Project. http://www.pmda.go.jp/safety/surveillance-analysis/0011.html
 
12) 齊尾武郎, 栗原千絵子. レギュラトリーサイエンス・ウォーズ-概念の混乱と科学論者の迷走. 臨床評価 2010 ; 38 : 177-188.
 
P.328 掲載の参考文献
1) 医薬品, 医療機器等の品質, 有効性及び安全性の確保等に関する法律 (昭和三十五年八月十日法律第百四十五号)
 
2) 医薬品の安全性に関する非臨床試験の実施の基準に関する省令 (平成九年三月二十六日厚生省令第二十一号) http://law.e-gov.go.jp/htmldata/H09/H09F03601000021.html
 
3) 「治験薬の製造管理, 品質管理等に関する基準 (治験薬GMP) について」(平成20年7月9日薬食発第0709002号厚生労働省医薬食品局長通知)
 
4) 医薬品の臨床試験の実施の基準に関する省令 (平成九年三月二十七日厚生省令第二十八号) http://law.e-gov.go.jp/htmldata/H09/H09F03601000028.html
 
5) 医薬品の臨床試験の実施の基準 (GCPの内容). 中央薬事審議会答申. 平成9年3月13日. http://www.jmacct.med.or.jp/plan/files/gcp_970313.pdf
 
6) 人を対象とする医学系研究に関する倫理指針 (平成26年文部科学省・厚生労働省告示第3号) http://www.lifescience.mext.go.jp/files/pdf/n1443_01.pdf
 
7) 臨床試験の一般指針 (平成10年4月21日医薬審第380号) https://www.pmda.go.jp/files/000156372.pdf
 
8) 「臨床試験のための統計的原則」について (平成10年11月30日医薬審第1047号) https://www.pmda.go.jp/int-activities/int-harmony/ich/0031.html
 
9) 「臨床試験における対照群の選択とそれに関連する諸問題」について (平成13年2月27日医薬審第136号) https://www.pmda.go.jp/int-activities/int-harmony/ich/0016.html
 
10) 医薬品の臨床試験及び製造販売承認申請のための非臨床安全性試験の実施についてのガイダンス (平成22年2月19日薬食審査発0219第4号) https://www.pmda.go.jp/files/000156948.pdf
 
P.335 掲載の参考文献
1) Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease : Progress and problems on the road to therapeutics. Science 2002 ; 297 : 353-356.
PubMed
2) Schenk D, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999 ; 400 : 173-177.
 
3) Orgogozo J-M, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ 42 immunization. Neurology 2003 ; 61 : 46-54.
 
4) Bard F, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000 ; 6 : 916-919.
 
5) Sevigny J, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 2016 ; 537 : 50-60.
 
6) Schor NF. What the halted phase 3 γ-secretase inhibitor trial may (or may not) be telling us. Ann Neurol 2011 ; 69 : 237-239.
 
7) La Spada AR, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991 ; 352 : 77-79.
 
8) Li M, et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol 1998 ; 44 : 249-254.
PubMed
9) Doyu M, et al. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 1992 ; 32 (5) : 707-710.
PubMed
10) Katsuno M, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002 ; 35 : 843-854.
 
11) Katsuno M, et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 2003 ; 9 : 768-773.
 
12) Banno H, et al. Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin : A pathogenic marker. Ann Neurol 2006 : 59 : 520-526.
PubMed
13) Banno H, et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 2009 ; 65 : 140-150.
PubMed
14) Katsuno M, et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study) : A multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010 ; 9 : 875-884.
PubMed
15) Hashizume A, et al. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy : Natural history-controlled study. J Neurol Neurosurg Psychiatry 2017 ; in press.
 
16) Fearnley JM, Lees AJ. Ageing and Parkinson's disease : Substantia nigra regional selectivity. Brain 1991 ; 114 : 2283-2301.
PubMed
P.342 掲載の参考文献
1) Green RC, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease : A randomized controlled trial. JAMA 2009 ; 302 : 2557-2564.
PubMed
2) Doody RS, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013 ; 369 : 341-350.
PubMed
3) Hemming ML, et al. Identification of beta-secretase (BACE1) substrates using quantitative proteomics. PLoS One 2009 ; 4 : e8477.
PubMed
4) Schenk D, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999 ; 400 : 173-177.
 
5) Nicoll JA, et al. Neuropathology of human Alzheirner disease after immunization with amyloid-beta peptide : A case report. Nat Med 2003 ; 9 : 448-452.
PubMed
6) Sevigny J, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 2016 ; 537 : 50-56.
 
7) Holmes, et al. Long-term effects of A beta 42 immunisation in Alzheimer's disease : Follow-up of a randomised, placebo-controlled phase I trial, Lancet 2008 ; 372 : 216-223.
PubMed
8) Yanamandra K, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013 ; 80 : 402-414.
PubMed
9) Boxer AL, et al. Davunetide in patients with progressive supranuclear palsy : A randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014 ; 13 : 676-685.
PubMed
10) Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004 ; 44 : 181-193.
PubMed
11) Xia D, et al. Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer's disease. Neuron 2015 ; 85 : 967-981.
PubMed
12) Tagawa K, et al. Comprehensive phosphoproteome analysis unravels the core signaling network that initiates the earliest synapse pathology in preclinical Alzheimer's disease brain. Hum Mol Genet 2015 ; 24 : 540-558.
PubMed
13) Fujita K, et al. HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer's disease. Sci Rep 2016 ; 6 : 31895.
PubMed
P.347 掲載の参考文献
1) Jucker M, et al. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med 2010 ; 16 : 1210-1214.
PubMed
2) Games D, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995 ; 373 : 523-527.
PubMed
3) Schenk D, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999 ; 400 : 173-177.
PubMed
4) Janus C, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000 ; 408 : 979-982.
 
5) Bard F, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000 ; 6 : 916-919.
 
6) Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature 2002 ; 415 : 462.
PubMed
7) Nicoll JA, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide : A case report. Nat Med 2003 ; 9 : 448-452.
PubMed
8) Sevigny J, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 2016 ; 537 : 50-56.
 
9) Bergman H, et al. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990 ; 249 : 1436-1438.
PubMed
10) Doi D, et al. Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease. Stem Cells 2012 ; 30 : 935-945.
 
11) Yoshimi K, et al. Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR-Cas platform. Nat Commun 2014 ; 5 : 4240.
PubMed
12) Sasaki E, et al. Generation of transgenic non-human primates with germline transmission. Nature 2009 ; 459 : 523-527.
PubMed
13) Kishi N, et al. Common marmoset as a new model animal for neuroscience research and genome editing technology. Dev Growth Differ 2014 ; 56 : 53-62.
PubMed

III. ここが知りたい - 今後の治療開発に向けて

P.355 掲載の参考文献
1) Tsuji S, et al ; Study Group on Ataxic Diseases. Sporadic ataxias in Japan--A population-based epidemiological study. Cerebellum 2008 ; 7 : 189-197.
 
2) Atsuta N, et al : Research Committee on the Neurodegenerative Diseases of Japan. Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis. J Neurol Sci 2009 ; 276 : 163-169.
PubMed
3) Fang F, et al. Familial aggregation of amyotrophic lateral sclerosis. Ann Neurol 2009 ; 66 : 94-99.
PubMed
4) Nakamura R, et al ; Japanese Consortium for Amyotrophic Lateral Sclerosis Research (JaCALS). Next-generation sequencing of 28 ALS-related genes in a Japanese ALS cohort. Neurobiol Aging 2016 ; 39 : 219.e1-8.
 
5) Ogaki K, et al ; Japanese Consortium for Amyotrophic Lateral Sclerosis research (JaCALS). Analysis of C9orf72 repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis. Neurobiol Aging 2012 ; 33 : 2527.e11-16.
 
6) Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 2013 ; 369 : 233-244.
PubMed
7) 熱田直樹ほか. 日本版ALSFRS-Rを用いた電話調査によるALS患者の評価-広域的前回き縦断調査への応用. Brain and Nerve 2011 ; 63 : 491-496.
 
8) Iida A, et al. A functional variant in ZNF512B is associated with susceptibility to amyotrophic lateral sclerosis in Japanese. Hum Mol Genet 2011 ; 20 : 3684-3692.
PubMed
9) Akimoto C, et al. High-Resolution Melting (HRM) Analysis of the Cu/Zn Superoxide Dismutase (SOD1) Gene in Japanese Sporadic Amyotrophic Lateral Sclerosis (SALS) Patients. Neurol Res Int 2011 ; 2011 : 165415.
PubMed
10) Takahashi Y, et al. ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am J Hum Genet 2013 ; 93 : 900-905.
 
11) Watanabe H, et al. A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. J Neurol Neurosurg Psychiatry 2016 ; 87 : 851-858.
 
12) Nakamura R, et al. Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry 2013 ; 84 : 1365-1371.
PubMed
13) Watanabe H, et al. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 2015 ; 16 : 230-236.
PubMed
14) Yokoi D, et al ; JaCALS. Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis. J Neurol 2016 ; 263 : 1129-1136.
PubMed
P.361 掲載の参考文献
1) 埜中征哉. 臨床のための筋病理, 第4版. 東京 : 日本医事新報社 ; 2014.
 
2) Emery AE. Population frequencies of inherited neuromuscular diseases--a world survey. Neuromuscul Disord 1991 ; 1 : 19-29.
 
3) 日本神経学会ほか (監修), 「デュシェンヌ型筋ジストロフィー診療ガイドライン」作成委員会 (編). デュシェンヌ型筋ジストロフィー診療ガイドライン 2014. 東京 : 南江堂 ; 2014.
 
4) Monaco AP, et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988 ; 2 : 90-95.
PubMed
5) Hoffman EP, et al. Dystrophin : The protein product of the Duchenne muscular dystrophy locus. Cell 1987 ; 51 : 919-928.
PubMed
6) Tuffery-Giraud S, et al. Genotype-phenotype analysis in 2.405 patients with a dystrophinopathy using the UMD-DMD database : A model of nationwide knowledgebase. Hum Mutat 2009 ; 30 : 934-945.
 
7) Angelini C, et al. Deflazacort in Duchenne dystrophy : Study of long-term effect. Muscle Nerve 1994 ; 17 : 386-391.
PubMed
8) Aartsma-Rus A, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009 ; 30 : 293-299.
PubMed
9) Summerton J, et al. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev 1997 ; 7 : 63-70.
PubMed
10) Saito T, et al. Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS One 2010 ; 5 : e12239.
PubMed
11) Ezzat K, et al. Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides. Nano Lett 2015 ; 15 : 4364-4373.
PubMed
12) Nakamura A, et al. Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J Clin Neurosci 2008 ; 15 : 757-763.
 
13) Aoki Y, et al. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A 2012 ; 109 : 13763-13768.
PubMed
14) Wirth B, et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet 2006 ; 119 : 422-428.
PubMed
P.367 掲載の参考文献
1) Fukuyama Y, et al. Congenital progressive muscular dystrophy of the Fukuyama type-clinical, genetic and pathological considerations. Brain Dev 1981 ; 3 : 1-29.
PubMed
2) Kobayashi K, et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998 ; 394 : 388-392.
PubMed
3) Colombo R, et al. Age and origin of the FCMD 3'-untranslated-region retrotransposal insertion mutation causing Fukuyama-type congenital muscular dystrophy in the Japanese population. Hum Genet 2000 ; 107 : 559-567.
PubMed
4) Yoshida A, et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase. POMGnT1. Dev Cell 2001 ; 1 : 717-724.
 
5) 金川基. ジストログリカンの糖鎖機能と筋ジストロフィー. 生化学 2014 ; 86 : 452-463.
 
6) Yoshida-Moriguchi T, et al. O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding. Science 2010 ; 327 : 88-92.
PubMed
7) Inamori K, et al. Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Science 2012 ; 335 : 93-96.
PubMed
8) Taniguchi-Ikeda M, et al. Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature 2011 ; 478 : 127-131.
PubMed
9) Kanagawa M, et al. Identification of a post-translational modification with ribitol-phosphate and its defect in muscular dystrophy. Cell Rep 2016 ; 14 : 2209-2223.
PubMed
10) Gerin I, et al. ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto α-dystroglycan. Nat Commun 2016 ; 7 : 11534.
 
P.378 掲載の参考文献
1) Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007 ; 131 : 861-872.
PubMed
2) Avior Y, et al. Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol 2016 ; 17 : 170-182.
PubMed
3) Dimos JT, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008 ; 321 : 1218-1221.
PubMed
4) Burkhardt MF, et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol Cell Neurosci 2013 ; 56 : 355-364.
PubMed
5) Ebert AD, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009 ; 457 : 277-280.
PubMed
6) Lee G, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009 ; 461 : 402-406.
PubMed
7) Lee G, et al. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol 2012 ; 30 : 1244-1248.
PubMed
8) Yagi T, et al. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum Mol Genet 2011 ; 20 : 4530-4539.
PubMed
9) Israel MA, et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012 ; 482 : 216-220.
PubMed
10) Choi SH, et al. A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 2014 ; 515 : 274-278.
PubMed
11) Xu X, et al. Prevention of β-amyloid induced toxicity in human iPS cell-derived neurons by inhibition of Cyclin-dependent kinases and associated cell cycle events. Stem Cell Res 2013 ; 10 : 213-227.
 
12) Numasawa-Kuroiwa Y, et al. Involvement of ER stress in dysmyelination of Pelizaeus-Merzbacher Disease with PLP1 missense mutations shown by iPSC-derived oligodendrocytes. Stem Cell Reports 2014 ; 2 : 648-661.
PubMed
13) Miller JD, et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 2013 ; 13 : 691-705.
PubMed
14) Lancaster MA, et al. Cerebral organoids model human brain development and microcephaly. Nature 2013 ; 501 : 373-379.
PubMed
15) Kadoshima T, et al. Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex. Proc Natl Acad Sci U S A 2013 ; 110 : 20284-20289.
PubMed
16) Sakaguchi H, et al. Generation of functional hippocampal neurons from self-organizing human embryonic stem cell-derived dorsomedial telencephalic tissue. Nat Commun 2015 ; 6 : 8896.
PubMed
17) Muguruma K, et al. Self-organization of polarized cerebellar tissue in 3D culture of human pluripotent stem cells. Cell Rep 2015 ; 10 : 537-550.
PubMed
18) Wataya T, et al. Minimization of exogenous signals in ES cell culture induces rostral hypothalamic differentiation. Proc Natl Acad Sci U S A 2008 ; 105 : 11796-11801.
PubMed
19) Ozone C, et al. Functional anterior pituitary generated in self-organizing culture of human embryonic stem cells. Nat Commun 2016 ; 7 : 10351.
PubMed
20) Nakano T, et al. Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell 2012 ; 10 : 771-785.
PubMed
21) Shimojima K, et al. CHCHD2 is down-regulated in neuronal cells differentiated from iPS cells derived from patients with lissencephaly. Genomics 2015 ; 106 : 196-203.
PubMed
22) Dang J, et al. Zika virus depletes neural progenitors in human cerebral organoids through activation of the innate immune receptor TLR3. Cell Stem Cell 2016 ; 19 : 258-265.
 
P.386 掲載の参考文献
1) Rosen DR, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993 ; 362 : 59-62.
PubMed
2) Aoki M, et al. Mild ALS in Japan associated with novel SOD mutation. Nat Genet 1993 ; 5 : 323-324.
PubMed
3) Suzuki N, et al. FALS with FUS mutation in Japan with early onset, rapid progress and basophilic inclusion. J Hum Genet 2010 ; 55 : 252-254.
PubMed
4) Akiyama T, et al. Genotype-phenotype relationships in familial amyotrophic lateral sclerosis with FUS/TLS mutations in Japan. Mutscle Nerve 2016 ; 54 : 398-404.
PubMed
5) Ichiyanagi N, et al. Establishment of In Vitro FUS-Associated Familial Amyotrophic Lateral Sclerosis Model Using Human Induced Pluripotent Stem Cells. Stem Cell Reports 2016 ; 6 : 496-510.
PubMed
6) Nagai M, et al. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis : Associated mutations develop motor neuron disease. J Neurosci 2001 ; 21 : 9246-9254.
PubMed
7) Sun W, et al. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J Neurosci 2002 ; 22 : 6537-6548.
 
8) Ishigaki A, et al. Intrathecal delivery of hepatocyte growth factor from the amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model. J Neuropathol Exp Neurol 2007 ; 66 : 1037-1044.
 
9) Kitamura K, et al. Hepatocyte growth factor promotes endogenous repair and functional recovery after spinal cord injury. J Neurosci Res 2007 ; 85 : 2332-2342.
PubMed
10) Kitamura K, et al. Human hepatocyte growth factor promotes functional recovery in primates after spinal cord injury. PLoS One 2011 ; 6 (11) : e27706.
PubMed
P.390 掲載の参考文献
1) Akiyama Y, et al. Transplantation of clonal neural precursor cells derived from adult human brain establishes functional peripheral myelin the rat spinal cord. Exp Neurol 2001 ; 167 : 27-39.
PubMed
2) Honmou O, et al. Restoration of normal conduction properties in demyelinated spinal cord axons in the adult rat by transplantation of exogenous Schwann cells. J Neurosci 1996 ; 16 : 3199-3208.
PubMed
3) Akiyama Y, et al. Remyelination of the spinal cord following intravenous delivery of bone marrow cells. Glia 2002 ; 39 : 229-236.
PubMed
4) Iihoshi S, et al. A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats. Brain Res 2004 ; 1007 (1-2) : 1-9.
PubMed
5) Inoue M, et al. Comparative analysis of remyelinating potential of focal and intravenous administration of autologous bone marrow cells into the rat demyelinated spinal cord. Glia 2003 ; 44 (2) : 111-118.
PubMed
6) Sasaki M, et al. Transplantation of an acutely isolated bone marrow fraction repairs demyelinated adult rat spinal cord axons. Glia 2001 ; 35 : 26-34.
PubMed
7) Honma T, et al. Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Exp Neurol 2006 ; 199 : 56-66.
 
8) Horita Y, et al. Intravenous administration of glial cell line-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. J Neurosci Res 2006 ; 84 : 1495-1504.
 
9) Komatsu K, et al. Therapeutic time window of mesenchymal stem cells derived from bone marrow after cerebral ischemia. Brain Res 2010 ; 1334 : 84-92.
PubMed
10) Liu H, et al. Neuroprotection by PlGF gene-modified human mesenchymal stem cells after cerebral ischaemia. Brain 2006 ; 129 : 2734-2745.
PubMed
11) Nomura T, et al. I. V. infusion of brain-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Neuroscience 2005 ; 136 : 161-169.
 
12) Omori Y, et al. Optimization of a therapeutic protocol for intravenous injection of human mesenchymal stem cells after cerebral ischemia in adult rats. Brain Res 2008 ; 1236 : 30-38.
PubMed
13) Onda T, et al. Therapeutic benefits by human mesenchymal stem cells (hMSCs) and Ang-1 gene-modified human mesenchymal stem cells after cerebral ischemia. J Cereb Blood Flow Metab 2008 ; 28 : 329-340.
PubMed
14) Sasaki M, et al. Development of a middle cerebral artery occlusion model in the nonhuman primate and a safety study of i. v. Infusion of human mesenchymal stem cells. PLoS One 2011 ; 6 : e26577.
 
15) Sasaki M, et al. BDNF-hypersecreting human mesenchymal stem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury. J Neurosci 2009 ; 29 (47) : 14932-14941.
PubMed
16) Suzuki J, et al. Bilateral cortical hyperactivity detected by fMRI associates with improved motor function following intravenous infusion of mesenchymal stem cells in a rat stroke model. Brain Res 2013 ; 1497 : 15-22.
 
17) Toyama K, et al. Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia. Exp Neurol 2009 ; 216 : 47-55.
PubMed
18) Osaka M, et al. Intravenous administration of mesenchymal stem cells derived from bone marrow after contusive spinal cord injury improves functional outcome. Brain Res 2010 ; 1343 : 226-235.
PubMed
19) Honmou O, et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 2011 ; 134 : 1790-1807.
PubMed
20) Honmou O, et al. Mesenchymal stem cells : Therapeutic outlook for stroke. Trends Mol Med 2012 ; 18 : 292-297.
PubMed
P.399 掲載の参考文献
1) Schenk D, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999 ; 400 (6740) : 173-177.
PubMed
2) Orgogozo JM, et al. Subacute meningoencephalitis in a subset of patients with AD after A beta 42 immunization. Neurology 2003 ; 61 (1) : 46-54.
 
3) Holmes C, et al. Long-term effects of A beta 42 immunisation in Alzheimer's disease : Follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008 ; 372 (9634) : 216-223.
PubMed
4) Farlow MR, et al. Long-term treatment with active A beta immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimers Res Ther 2015 ; 7 (1) : 23.
PubMed
5) Salloway S, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014 ; 370 (4) : 322-333.
PubMed
6) Doody RS, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014 ; 370 (4) : 311-321.
PubMed
7) Siemers ER, et al. Phase 3 solanezumab trials : Secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement 2016 ; 12 (2) : 110-120.
PubMed
8) Klunk WE, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004 ; 55 (3) : 306-319.
PubMed
9) Sevigny J, et al. The antibody aducanumab reduces A beta plaques in Alzheimer's disease. Nature 2016 ; 537 (7618) : 50-56.
PubMed
10) Logovinsky V, et al. Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective A beta antibody. Alzheimers Res Ther 2016 ; 8 (1) : 14.
PubMed
11) Dubois B, et al. Preclinical Alzheimer's disease : Definition, natural history, and diagnostic criteria. Alzheimers Dement 2016 ; 12 (3) : 292-323.
PubMed
12) Sperling RA, et al. Toward defining the preclinical stages of Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer Dement 2011 ; 7 (3) : 280-292.
PubMed
13) Lopera F, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997 ; 277 (10) : 793-799.
 
14) Acosta-Baena N, et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease : A retrospective cohort study. Lancet Neurol 2011 ; 10 (3) : 213-220.
PubMed
15) Klunk WE, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004 ; 55 (3) : 306-319.
PubMed
P.405 掲載の参考文献
1) 里宇明元. 脳卒中後重度上肢麻痺の回復に向けての挑戦-Brain Machine Interface技術を利用した新たなリハビリテーション機器の開発. Ipn J Rehabil Med 2016 ; 53 : 465-470.
 
2) 里宇明元. 脳科学研究と新しい治療法-脳卒中片麻痺上肢の機能回復に向けて. 診断と治療 2014 ; 102 : 361-366.
Medical*Online
3) Langhorne P, et al. Motor recovery after stroke : A systematic review. Lancet Neurol 2009 ; 8 : 741-754.
PubMed
4) Hashimoto Y, et al. Change in brain activity through virtual reality-based brain-machine communication in a chronic tetraplegic subject with muscular dystrophy. BMC Neurosci 2010 ; 11 : 117.
 
5) Shindo K, et al. Effects of neurofeedback training with an electroencephalogram-based Brain Computer Interface for hand paralysis in patients with chronic stroke : A preliminary case series study. J Rehabil Med 2011 ; 43 : 951-957.
PubMed
6) Takemi M, et al. Event-related desynchronization reflects downregulation of intracortical inhibition in human primary motor cortex. J Neurophysiol 2013 ; 110 : 1158-1166.
PubMed
7) Takemi M, et al. Sensorimotor event-related desynchronization represents the excitability of human spinal motoneurons. Neuroscience 2015 ; 297 : 58-67.
PubMed
8) Kasashima Y, et al. Modulation of event related desynchronization during motor imagery with transcranial direct current stimulation (tDCS) in patients with chronic hemiparetic stroke. Exp Brain Res 2012 ; 221 : 263-268.
PubMed
9) Ono T, et al. Multimodal sensory feedback associated with motor attempts alters BOLD responses to paralyzed hand movement in chronic stroke patients. Brain Topogr 2015 ; 28 : 340-351.
PubMed
10) Ono T, et al. Brain-computer interface with somatosensory feedback improves functional recovery from severe hemiplegia due to chronic stroke. Front Neuroeng 2014 ; 7 : 19.
 
11) Mukaino M, et al. Efficacy of brain-computer interface-driven neuromuscular electrical stimulation for chronic paresis after stroke. J Rehabil Med 2014 ; 46 : 378-382.
PubMed
12) Kasashima-Shindo Y, et al. Brain-computer interface training combined with transcranial direct current stimulation in patients with chronic severe hemiparesis : Proof of conept study. J Rehabil Med 2015 ; 47 : 318-324.
 
13) Page SJ, et al. Clinically important for the upper extremity Fugl-Meyer scale in people with minimal to moderate impairment due to chronic stroke. Phys Ther 2012 ; 92 : 791-798.
 
14) Fujiwara T, et al. Motor improvement and corticospinal modulation induced by hybrid assistive neuromuscular dynamic stimulation (HANDS) therapy in patients with chronic stroke. Neurorehabil Neural Repair 2009 ; 23 : 125-132.
PubMed
P.412 掲載の参考文献
1) Hasegawa M. Molecular mechanisms in the pathogenesis of Alzheimer's disease and tauopathies-prion-like seeded aggregation and phosphorylation. Biomolecules 2016 ; 6 (2). pii : E24.
 
2) Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991 ; 82 : 239-259.
PubMed
3) Hasegawa M, et al. α-Synuclein : Experimental Pathology. Cold Spring Harb Perspect Med 2016 ; 6 (9). pii : a024273.
 
4) Baker HF, et al. Evidence for the experimental transmission of cerebral beta-amyloidosis to primates. Int J Exp Pathol 1993 ; 74 : 441-454.
PubMed
5) Meyer-Luehmann M, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006 ; 313 : 1781-1784.
PubMed
6) Clavaguera F, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009 ; 11 : 909-913.
PubMed
7) Clavaguera F, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A 2013 ; 110 : 9535-9540.
PubMed
8) Sanders DW, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 2014 ; 82 : 1271-1288.
PubMed
9) Nonaka T, et al. Seeded aggregation and toxicity of ｛alpha｝ -synuclein and tau : Cellular models of neurodegenerative diseases. J Biol Chem 2010 ; 285 : 34885-34895.
PubMed
10) Volpicelli-Daley LA, et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011 ; 72 : 57-71.
 
11) Desplats P, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009 ; 106 : 13010-13015.
PubMed
12) Luk KC, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012 ; 338 : 949-953.
 
13) Masuda-Suzukake M, et al. Prion-like spreading of pathological α-synuclein in brain. Brain 2013 ; 136 : 1128-1138.
 
14) Nonaka T, et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep 2013 ; 4 : 124-134.
PubMed
15) Munch C, et al. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci U S A 2011 ; 108 : 3548-3553.
PubMed
16) Sevigny J, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 2016 ; 537 : 50-56.
 
17) Kondo A, et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature 2015 ; 523 : 431-436.
PubMed
18) Lu KP, et al. Potential of the antibody against cis-phosphorylated tau in the early diagnosis, treatment, and prevention of alzheimer disease and brain injury. JAMA Neurol 2016 ; 73 : 1356-1362.
PubMed
19) Frontzek K, et al. Amyloid-β pathology and cerebral amyloid angiopathy are frequent in iatrogenic Creutzfeldt-Jakob disease after dural grafting. Swiss Med Wkly 2016 ; 146 : w14287.
 
20) Preusser M, et al. Alzheimer-type neuropathology in a 28 year old patient with iatrogenic Creutzfeldt-Jakob disease after dural grafting. J Neurol Neurosurg Psychiatry 2006 ; 77 : 413-416.
 
21) Simpson DA, et al. Iatrogenic Creutzfeldt-Jakob disease and its neurosurgical implications. J Clin Neurosci 1996 ; 3 : 118-123.
PubMed
22) Jaunmuktane Z, et al. Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature 2015 ; 525 : 247-250.
 
P.416 掲載の参考文献
1) 北谷照雄ほか. ニーマン・ピック病C型治療薬 ミグルスタット (ブレーザベス(R) カプセル 100mg) の薬理学的特性および臨床効果. 日本薬理学雑誌 2013 ; 141 : 160-167.
Medical*Online
2) Lachmann RH. Miglustat. Oxford GlycoSciences/Actelion. Curr Opin Investig Drugs 2003 ; 4 : 472-479.
PubMed
3) Patterson MC, et al. Miglustat for treatment of Niemann-Pick C disease : A randomised controlled study. Lancet Neurol 2007 ; 6 : 765-772.
 
4) Pineda M, et al. Miglustat in patients with Niemann-Pick disease Type C (NP-C) : A multicenter observational retrospective cohort study. Mol Genet Metab 2009 ; 98 : 243-249.
 
5) Wraith JE, et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C : Long-term data from a clinical trial. Mol Genet Metab 2010 ; 99 : 351-357.
PubMed
6) Patterson MC, et al. Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C : An observational cohort study. Orphanet J Rare Dis 2015 ; 10 : 65.
 
7) Sakiyama Y, et al. Abnormal copper metabolism in Niemann-Pick disease type C mimicking Wilson's disease. Neurol Clin Neurosci 2014 ; 2 : 193-200.
 
8) Szakszon K, et al. Complete recovery from psychosis upon miglustat treatment in a juvenile Niemann-Pick C patient. Eur J Paediatr Neurol 2014 ; 18 : 75-78.
 
9) Zarowski M, et al. Treatment of cataplexy in Niemann-Pick disease type C with the use of miglustat. Eur J Paediatr Neurol 2011 ; 15 : 84-87.
PubMed
10) Belmatoug N, et al. Gastrointestinal disturbances and their management in miglustat-treated patients. J Inherit Metab Dis 2011 ; 34 : 991-1001.
PubMed
11) Lukina E, et al. Eliglustat an investigational oral therapy for Gaucher disease type 1 : Phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis 2014 ; 53 : 274-276.
PubMed
12) Mistry PK, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1 : The ENGAGE randomized clinical trial. JAMA 2015 ; 313 : 695-706.
PubMed
13) Cox TM, et al. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy : A phase 3 randomised open-label non-inferiority trial. Lancet 2015 ; 385 : 2355-2362.
PubMed
14) 井田博幸. 基質合成抑制療法. 小児科診療 2016 ; 79 : 759-765.
Medical*Online
15) Germain DP, et al. Treatment of Fabry's disease with the pharmacologic chaperone migalastat. N Engl J Med 2016 ; 375 : 545-555.
PubMed
Coutinho MF, et al. Less is more : Substrate reduction therapy for lysosomal storage disorders. Int J Mol Sci 2016 ; 17 : 1065.
 
大野耕策 (編). ニーマン・ピック病C型の診断と治療. 大阪 : 医薬ジャーナル社 ; 2015.
 
Shemesh E, et al. Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database of Syst Rev 2015 ; (3) : CD010324.
PubMed
P.422 掲載の参考文献
1) Sipe JD, et al. Amyloid fibril protein nomenclature : 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012 ; 19 : 167-170.
 
2) Nakagawa M, et al. Carpal tunnel syndrome : A common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid 2016 ; 23 : 58-63.
PubMed
3) Sekijima Y, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell 2005 ; 121 : 73-85.
PubMed
4) Miroy GJ, et al. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A 1996 ; 93 : 15051-15056.
PubMed
5) Miller SR, et al. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 2004 ; 84 : 545-552.
PubMed
6) Sekijima Y, et al. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006 ; 13 : 236-249.
PubMed
7) Berk JL, et al. Repurposing diflunisal for familial amyloid polyneuropathy : A randomized clinical trial. JAMA 2013 ; 310 : 2658-2667.
PubMed
8) Coelho T, et al. Tafamidis for transthyretin familial amyloid polyneuropathy : A randomized, controlled trial. Neurology 2012 ; 79 : 785-792.
PubMed
9) Sekijima Y, et al. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology 2016 ; 87 : 773-781.
PubMed
P.428 掲載の参考文献
1) Brady RO. Enzyme replacement therapy for lysosomal diseases. Annu Rev Med 2006 ; 57 : 286-296.
 
2) Fan JQ, et al. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1999 ; 5 : 112-115.
PubMed
3) Suzuki Y, et al. β-Galactosidase deficiency (β-Galactosidosis) : GM1 gangliosidosis and Morquio B disease. In : Valle D, et al (editors), The Online Metabolic and Molecular Bases of Inherited Disease. New York : McGraw-Hill ; 2008, pp. 1-101.
 
4) Matsuda J, et al. Chemical chaperone therapy for brain pathology in GM1-gangliosidosis. Proc Natl Acad Sci U S A 2003 ; 100 : 15912-15917.
PubMed
5) Aguilar-Moncayo M, et al. Tuning glycosidase inhibition through aglycone interactions : Pharmacological chaperones for Fabry disease and GM1 gangliosidosis. Chem Commun 2012 ; 48 : 6514-6516.
PubMed
6) Iwasaki H, et al. Fibroblast screening for chaperone therapy in β-galactosidosis. Brain Dev 2006 ; 28 : 482-486.
 
7) Higaki K, et al. Chemical chaperone therapy : Chaperone effect on mutant enzyme and cellular pathology in β-galactosidase deficiency. Hum Mutat 2011 ; 32 : 843-852.
 
8) Takai T, et al. A bicyclic 1-deoxygalactonojirimycin derivatie as a novel pharmacological chaperone for GM1 gangliosidosis. Mol Ther 2013 ; 21 : 526-532.
 
9) Suzuki Y, et al. Chemical chaperone therapy : Clinical effect in murine GM1-gangliosidosis. Ann Neurol 2007 ; 62 : 671-675.
PubMed
10) Suzuki Y, et al. Therapeutic chaperone effect on N-octyl-4-epi-β-valienamine on murine GM1-gangliosidosis. Mol Genet Metab 2012 ; 106 : 92-98.
 
11) Germain DP, et al. Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease : Report from two phase 2 clinical studies. Orphanet J Rare Dis 2012 ; 7 : 91.
 
12) Zimran A, et al. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cell Mol Dis 2013 ; 50 : 134-137.
PubMed
13) Narita A, et al. Ambroxol chaperone therapy for neuronopathic Gaucher disease : A pilot study. Ann Clin Transl Neurol 2016 ; 3 : 200-215.
PubMed
14) Clarke JT, et al. An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Mol Genet Metab 2011 ; 102 : 6-12.
PubMed
15) Porto C, et al. Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcystein. Mol Ther 2012 ; 20 : 2201-2211.
 
16) Benjamin ER, et al. Co-administration with the pharmacological chaperone AT1001 increaes recombinant human α-galactosidase A tissue uptake and improve substrate reduction in Fabry mice. Mol Ther 2012 ; 20 : 717-726.
 
17) Aflaki E, et al. A new glucocerebrosidase chaperone reduces α-Synuclein and gycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism. J Neurosci 2016 ; 36 : 7441-7452.
 
P.433 掲載の参考文献
1) Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : A STAR*D report. Am J Psychiatry 2006 ; 163 : 1905-1917.
 
2) 本橋伸高. ECTマニュアル-科学的精神医学をめざして. 東京 : 医学書院 ; 2000.
 
3) Lisanby SH, et al. Safety and feasibility of magnetic seizure therapy (MST) in major depression : Randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology 2003 ; 28 : 1852-1865.
PubMed
4) McClintock SM, et al. A systematic review of the neurocognitive effects of magnetic seizure therapy. Int Rev Psychiatry 2011 ; 23 : 413-423.
PubMed
5) Fitzgerald PB, et al. Pilot study of the clinical and cognitive effects of high-frequency magnetic seizure therapy in major depressive disorder. Depress Anxiety 2013 ; 30 : 129-136.
PubMed
6) Spellman T, et al. Differential effects of high-dose magnetic seizure therapy and electroconvulsive shock on cognitive function. Biol Psychiatry 2008 ; 63 : 1163-1170.
PubMed
7) Lisanby SH, et al. Deliberate seizure induction with repetitive transcranial magnetic stimulation in nonhuman primates. Arch Gen Psychiatry 2001 ; 58 : 199-200.
PubMed
8) Lisanby SH, et al. Magnetic seizure therapy of major depression. Arch Gen Psychiatry 2001 ; 58 : 303-305.
PubMed
9) Rowny SB, et al. Translational development strategy for magnetic seizure therapy. Exp Neurol 2009 ; 219 : 27-35.
PubMed
10) 鬼頭伸輔 (編). うつ病のTMS療法. 東京 : 金原出版 ; 2016.
 
11) Kayser S, et al. Antidepressant effects, of magnetic seizure therapy and electroconvulsive therapy, in treatment-resistant depression. J Psychiatr Res 2011 ; 45 : 569-576.
PubMed
12) Kirov G, et al. Quick recovery of orientation after magnetic seizure therapy for major depressive disorder. Br J Psychiatry 2008 ; 193 : 152-155.
PubMed
13) Rowny SB, et al. Differential heart rate response to magnetic seizure therapy (MST) relative to electroconvulsive therapy : A nonhuman primate model. Neuroimage 2009 ; 47 : 1086-1091.
PubMed
14) Kayser S, et al. Comparable seizure characteristics in magnetic seizure therapy and electroconvulsive therapy for major depression. Eur Neuropsychopharmacol 2013 ; 23 : 1541-1550.
PubMed
15) Demirtas-Tatlidede A, et al. Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders? Neuropharmacology 2013 ; 64 : 566-578.
PubMed
16) Serafini G, et al. The effects of repetitive transcranial magnetic stimulation on cognitive performance in treatment-resistant depression. A systematic review. Neuropsychobiology 2015 ; 71 : 125-139.
PubMed
Deng ZD, et al. Neuromodulation for mood and memory : From the engineering bench to the patient bedside. Curr Opin Neurobiol 2015 ; 30 : 38-43.
 
Allan CL, Ebmeier KP. The use of ECT and MST in treating depression. Int Rev Psychiatry 2011 ; 23 : 400-412.
PubMed
P.439 掲載の参考文献
1) Miyake S, et al. Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis. with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. PLoS One 2015 ; 10 (9) : e0137429.
PubMed
2) Chen J, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rip 2016 ; 6 : 28484.
 
3) Berer K, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011 ; 479 (7374) : 538-541.
PubMed
4) Lee YK, et al. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2011 ; 108 Suppl 1 : 4615-4622.
 
5) van Nood E, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013 ; 368 (5) : 407-415.
PubMed
6) Surawicz CM, et al. Guidelines for diagnosis, treatment. and prevention of Clostridium difficile infections. Am J Gastroenterol 2013 ; 108 (4) : 478-498 ; quiz 499.
PubMed
7) Debast SB, et al. European Society of Clinical Microbiology and Infectious Diseases : Update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014 ; 20 (Suppl 2) : 1-26.
 
8) Li SS, et al. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science 2016 ; 352 (6285) : 586-589.
PubMed
9) Matsuoka K, et al. Fecal microbiota transplantation for gastrointestinal diseases. Keio J Med 2014 ; 63 (4) : 69-74.
PubMed
10) Kassam Z, et al. Fecal microbiota transplantation for Clostridium difficile infection : Systematic review and meta-analysis. Am J Gastroenterol 2013 ; 108 (4) : 500-508.
PubMed
11) Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum Infect Dis 2015 ; 2 (1) : ofv004.
PubMed
12) Lee CH, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection : A randomized clinical trial. JAMA 2016 ; 315 (2) : 142-149.
PubMed
13) Youngster I, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014 ; 312 (17) : 1772-1778.
PubMed
14) Petrof EO, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection : 'RePOOPulating' the gut. Microbiome 2013 ; 1 (1) : 3.
PubMed
15) Khanna S, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis 2016 ; 214 (2) : 173-181.
 
16) Weingarden AR, et al. Ursodeoxycholic acid inhibits Clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection. J Clin Gastroenterol 2016 ; 50 (8) : 624-630.
PubMed
Smits LP, et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013 ; 145 : 946-953.
PubMed
Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol 2016 ; 13 (9) : 508-516.
PubMed
P.444 掲載の参考文献
1) 佐橋健太郎ほか. 脊髄性筋萎縮症の最近のスプライシング病態, 治療研究. Brain and Nerve 2014 ; 66 : 1471-1480.
 
2) Hua Y, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010 ; 24 : 1634-1644.
 
3) Passini MA, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 2011 ; 3 : 72ra18.
 
4) Sahashi K, et al. TSUNAMI : An antisense method to phenocopy splicing-associated diseases in animals. Genes Dev 2012 ; 26 : 1874-1884.
PubMed
5) Sahashi K, et al. Pathological impact of SMN2 mis-splicing in adult SMA mice. EMBO Mol Med 2013 ; 5 : 1586-1601.
PubMed
6) Rigo F, et al. Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J Pharmacol Exp Ther 2014 ; 350 : 46-55.
PubMed
7) Hua Y, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011 ; 478 : 123-126.
PubMed
8) Hua Y, et al. Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models. Genes Dev 2015 ; 29 : 288-297.
PubMed
9) Chiriboga CA, et al. Results from a phase 1 study of nusinersen (ISIS-SMN (Rx)) in children with spinal muscular atrophy. Neurology 2016 ; 86 : 890-897.
PubMed
10) Finkel RS, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen : A phase 2, open-label, dose-escalation study. Lancet 2016 ; 388 : 3017-3026.
PubMed

書評

最近チェックした商品履歴

Loading...